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Summary 
 
The genes encoding fatty acid binding protein 2 (FABP2), microsomal triglyceride transfer 
protein (MTTP) and prostaglandin E synthase 2 (PTGES2) are involved in the regulation of 
the metabolism of dietary fat. Variants of the FABP2, MTTP and PTGES2 genes are 
associated with traits of the metabolic syndrome (MetS). This work expands the knowledge 
about the influence of the 3 gene loci on diverse MetS traits via association analysis in the 
KORA cohort with more than 8000 participants. Further, functional analysis of the FABP2 
promoter was carried out in cell culture regarding a PPARγ/RXRα regulation. 
 
FABP2 mediates intestinal absorption and cytosolic transport of non-esterified long chain free 
fatty acids (FA) as well as their secretion into triglyceride rich chylomicrons. Further, FABP2 
transports FA into the nucleus as ligands for transcription factors (TF). The FABP2 promoter 
comprises polymorphisms c.-80_-79insT, c.-136_-132delAGTAG, c.-168_-166delAAGinsT, 
c.-260G>A, c.-471G>A and c.-778G>T, which result in two haplotypes A and B. Studies in 
relatively small cohorts provide preliminary evidence that FABP2 promoter haplotypes are 
associated with type 2 diabetes (T2D) and BMI.  
Here, the influence of haplotypes on BMI was examined via linear regression analysis of 8072 
male and female participants of the KORA cohort. A reduction of -0.39 BMI units (p=0.02) in 
homozygous male FABP2 promoter haplotype B carrier was found. Carrier of haplotype B 
(AB+BB) showed a significant decrease in BMI of -0.19 BMI units (p=0.03). In accordance, a 
significant reduction in BMI of the minor haplotype carrier in the BMI point categories of 25-
30 (-0.10 BMI units, p=0.03) and <30 (-0.37 BMI units, p=0.02) were found. Female carriers 
showed no association with BMI. 
Functional analysis of haplotypes by Rosiglitazone stimulated PPARγ/RXRα displays a 2-fold 
higher activity of haplotype B than A. As shown by chimeric FABP2 promoter constructs, the 
higher responsiveness of FABP2 haplotype B is mainly but not solely determined by 
polymorphism c.-471G>A. As shown by electro mobility shift assays and promoter reporter 
assays, OCT1 interacts with the -471 region of FABP2 promoters, induces the activities of 
both FABP2 promoter haplotypes and abolishes the different activities of haplotypes induced 
by Rosiglitazone stimulated PPARγ/RXRα.  
 
MTTP is a key regulator in the assembly and secretion of chylomicrons and VLDL in the 
intestine and in liver. Associations between MTTP variants and traits of the MetS are carried 
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out in relatively small cohorts and are not consistent. Seven htSNPs covering a 52 kb region 
of the MTTP locus and two cSNPs (I128T, H297Q) were analysed for MetS trait alteration 
via linear regression in 7582 participants of the KORA study cohort. A MTTP haplotype 
containing the minor allele of H297Q showed a significant decrease of -0.64 BMI units 
(p=0.04) in females but not in males. Only females carrying the Q-allele showed a decrease in 
BMI (Q-carrier: -0.26 BMI unit, p=0.02; Q/Q: -0.66 BMI units, p=0.01), waist circumference 
(Q-carrier: -0.66 cm, p=0.01; Q/Q -1.44 cm, p=0.01) and total cholesterol (Q-carrier: -0.05 
mmol/l, p=0.03; Q/Q: -0.11 mmol/l, p=0.03). Males revealed no association with any of the 
three measured traits of the MetS. 
 
PTGES2 is required for production of the antilipolytic compound prostaglandin E2. The  
H-allele of the R298H polymorphism in the PTGES2 gene was associated with lower risk of 
T2D. To explore a PTGES2 gene influence on BMI alteration, the R298H SNP and three 
htSNPs covering a 20 kb gene region were analysed in the KORA study cohort with 8079 
participants. A statistically significant difference in BMI between the heterozygous PTGES2 
R298H genotype and the homozygous R/R genotype was found in males but not in females. 
Males with the R/H genotype showed a decrease in BMI of -0.30 BMI units (p=0.02) in 
comparison to R/R males. A haplotype comprising the minor allele of PTGES2 R298H 
showed a significant decrease of -0.19 BMI units in males (p=0.04) but not in females. Other 
haplotypes and single htSNPs were not significantly associated with BMI.  
 
Association analysis in the KORA cohort with more than 8000 participants revealed 
association between BMI and polymorphisms of the FABP2 promoter and the MTTP and 
PTGES2 genes. The MTTP SNP H297Q and related haplotypes are also associated with waist 
circumference and total cholesterol. Functional analysis exhibited, that the FABP2 promoter 
haplotype B is 2-fold more inducible by PPARγ/RXRα than haplotype A. This difference is 
caused by polymorphism c.-471G>A. In addition, OCT1 was identified as a TF regulating the 
FABP2 promoter. In conclusion, variants of the FABP2, MTTP and PTGES2 genes, which 
are involved in fat metabolism, contribute to the development of the MetS. 
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Zusammenfassung 
 
Das Fettsäure-Bindungsprotein 2 (FABP2), das mikrosomalen Triglycerid-Transfer Protein 
(MTTP) und die Prostaglandin E Synthase 2 (PTGES2) sind beteiligt an der Regulierung des 
Fettstoffwechsels. Polymorphismen in den Genen vom FABP2, MTTP und PTGES2 sind mit 
Markern des Metabolischen Syndroms (MetS) assoziiert. Diese Arbeit erweitert das Wissen 
über den Zusammenhang zwischen diesen 3 Gen Bereichen und Markern des MetS auf der 
Basis von Assoziationsstudien in der KORA Kohorte mit mehr als 8000 Teilnehmern. 
Weiterhin wurde die Regulation des FABP2 Promotors durch PPARγ/RXRα funktionell in 
einem Zellkulturansatz untersucht. 
 
FABP2 reguliert die Absorption und den zytosolischen Transport von nicht veresterten 
langkettigen freien Fettsäuren (FS) sowie deren Einbau in Chylomikronen im Darm. 
Weiterhin transportiert FABP2 FS in den Zellkern, in dem diese als Liganden für 
Transkriptionsfaktoren fungieren. Der FABP2 Promotor zeigt die Polymorphismen  
c.-80_-79insT, c.-136_-132delAGTAG, c.-168_-166delAAGinsT, c.-260G>A, c.-471G>A 
und c.-778G>T, die in den Haplotypen A and B resultieren. Studien in kleinen Kohorten 
zeigten Assoziationen der FABP2 Promotor Haplotypen mit Diabetes Typ 2 (T2D) und BMI. 
Lineare Regressions-Analysen der beiden Haplotypen im Bezug auf den BMI von 8072 
Männern und Frauen der KORA Kohorte offenbarte eine Reduktion um -0.39 BMI Einheiten 
(E.) (p=0.02) von homozygoten männlichen FABP2 Promotor Haplotyp B-Trägern. Generell 
hatten Männer mit dem Haplotyp B einen um -0.19 E. (p=0.03) signifikant erniedrigten BMI. 
Übereinstimmend hatten Träger des seltenen Allels eine BMI Erniedrigung in den Gruppen 
mit einem BMI von 25-30 (-0.10 E., p=0.03) und <30 (-0.37 E., p=0.02). Weibliche Träger 
des seltenen Allels zeigten keine signifikanten Assoziationen. Funktionelle Untersuchungen 
der FABP2 Promotor Haplotypen nach PPARγ/RXRα Transfektion führten zu einer 2-fach 
erhöhten Aktivität des Haplotyps B im Vergleich zu A im Zellkulturansatz. FABP2 Promotor 
Chimären zeigten, dass die stärkere Aktivierbarkeit des Haplotyps B wesentlich von dem  
c.-471G>A SNP abhängig ist. Elektro Mobility Shift Assays und Promotor Reporter Analysen 
zeigten eine Promotor aktivierende Bindung von OCT1 im Bereich des c.-471 SNP. Die 
haplotypen-spezifische Induktion durch PPARγ/RXRα wurde dadurch aufgehoben.  
 
MTTP ist ein Schlüsselenzym in der Bildung und der Sekretion von Chylomikronen und 
VLDL im Darm und in der Leber. Assoziationsstudien zwischen MTTP SNPs und Markern 
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des MetS, besonders Lipid-Werten, wiesen in kleinen Kohorten widersprüchliche Ergebnisse 
auf. 7 htSNPs, sowie 2 cSNPs (I128T, H297Q), die eine 52 kb Region des MTTP Locus 
umspannen, wurden auf ihr MetS Marker veränderndes Potential mittels Linearer Regression 
in 7582 Teilnehmern der KORA Kohorte hin untersucht. Ausschließlich weibliche Träger 
eines Haplotyps mit dem seltenen Allel des H297Q SNP zeigten eine signifikante 
Erniedrigung des BMIs um -0.64 E. (p=0.03). Ausschließlich Frauen mit einem Q-Allel 
zeigten Verminderungen des BMIs (Q- Träger: -0.26 BMI E., p=0.02; Q/Q: -0.66 BMI E., 
p=0.01), des Hüftumfangs (Q- Träger: -0.66 cm, p=0.01; Q/Q -1.44 cm, p=0.01) und des 
gesamt Cholesterins (Q- Träger: -0.05 mmol/l, p=0.03; Q/Q: -0.11 mmol/l, p=0.03). 
Männliche Träger des Q-Allels wiesen keine Veränderung dieser Parameter auf. 
 
PTGES2 bildet das antilipolytische Prostaglandin E2. Das H-Allel des R298H SNP im 
PTGES2 Gen ist mit einem erniedrigten T2D Risiko assoziiert. Um den Einfluss von PTGES2 
SNPs auf BMI Veränderungen zu untersuchen, wurden der R298H SNP und 3 htSNPs, 
welche eine 20 kb Region des PTGES2 Gens umspannen, in der KORA Kohorte mit 8079 
Teilnehmern analysiert. Ein statistisch signifikanter Unterschied zwischen BMI und 
heterozygoten Trägern des R298H SNP im Vergleich zu Trägern des häufigen Allels wurde 
ausschließlich in Männern gefunden. Träger des R/H Genotyps wiesen eine Reduktion um  
-0.30 BMI E. (p=0.02) auf. Männer die einen 298H Haplotyp aufwiesen zeigten einen um  
-0.19 E. erniedrigten BMI (p=0.04). Weiteren htSNPs oder Haplotypen zeigten keine 
Assoziationen zu einem veränderten BMI. 
 
Lineare Regressions-Analysen in der KORA Kohorte (n>8000) zeigten Assoziationen 
zwischen dem BMI und Polymorphismen im FABP2 Promotor und den Genen des MTTP 
und der PTGES2. Der MTTP H297Q SNP ist weiterhin mit Veränderungen im Hüftumfang 
und des Gesamt Cholesterins assoziiert. Funktionelle Analysen des FABP2 Promotors 
zeigten, dass die 2-fach höhere Aktivierbarkeit des Haplotyps B durch PPARγ/RXRα durch 
den SNP c.-471G>A hervorgerufen wird. Zusätzlich wurde OCT1 als ein Transkriptionsfaktor 
identifiziert, der den FABP2 Promotor reguliert. Zusammenfassend kann gesagt werden, dass 
Polymorphismen in den Genen des FABP2, MTTP und PTGES2, die für den Fettstoffwechsel 
wichtig sind, zur Entstehung des MetS beitragen. 
General introduction – FABP2 
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General introduction 
 
The metabolic syndrome (MetS) encompasses the most prevalent diseases in the western 
world including obesity, glucose and insulin disturbances, dislipidemia and high blood 
pressure [1]. These traits are accompanied by cardiovascular disease (CVD) and type 2 
diabetes mellitus (T2D). T2D incidence is projected to double to 350 million cases by the year 
2030 [2, 3]. With the completion of the Human Genome Project in 2003 [4] and the 
International HapMap Project in 2005 [5] the possibility to identify genetic variants 
associated with MetS was considerably enhanced resulting in numerous candidate gene 
approaches. Many candidates associated with MetS traits in initial studies could not be 
confirmed in further populations. This multitude of (unverified) candidate genes is unlikely to 
be solely false positives. In fact, especially the disease-associations of polymorphisms in 
small cohorts strongly depend on a variety of gene-gene and/or gene-environment interactions 
like food composition [6].  
The aim of this work was to expand the knowledge about the effects of selected 
polymorphisms in fat metabolism genes previously associated with traits of MetS and T2D. 
Therefore more than 8000 participants were genotyped in the KORA cohort for variants in the 
fatty acid binding protein 2 (FABP2) promoter, the gene loci of the microsomal triglyceride 
transfer protein (MTTP) and the prostaglandin E synthase 2 (PTGES2). Further functional 
analysis of the FABP2 promoter was carried out in cell culture regarding a PPARγ/RXRα 
regulation. 
 
 
The fatty acid binding protein 2 (FABP2) promoter 
The FABP family was first described 1982 after isolation from rat liver [7]. With its function 
of hydrophobic molecule binding the FABP family belongs to the calycin superfamily and is 
conserved in vertebrates and invertebrates [8]. A more precise classification of the vertebrate 
cytoplasmic FABPs was made, according to the tissue in which their expression was first 
detected, into liver FABP (L-FABP or FABP1), intestinal FABP (I-FABP or FABP2), heart 
FABP (H-FABP or FABP3), adipocyte FABP (A-FABP or FABP4), epidermal FABP (E-
FABP or FABP5), ileal FABP (Il-FABP or FABP6), brain FABP (B-FABP or FABP7), 
myelin FABP (MP2 or FABP8) and testis FABP (T-FABP or FABP9). Nonetheless, their 
expression is not necessarily restricted to their eponymous tissue [9].  
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Despite their differences in protein sequence, the molecular weight of 14 to 15 kDa and the 
tertiary structure are features shared by all family members. As illustrated in Fig. 1 the protein 
forms a twisted β-barrel surrounding a hydrophobic core, which is composed of 10 
antiparallel β-strands, which are organized into 2 β-sheets oriented nearly orthogonally [10]. 
One end of the β-barrel is capped by a small helix-turn-helix motif. Within the β-barrel a large 
water-filled cavity lined with polar and hydrophobic amino acids (aa) is responsible for 
sequestering the carboxylate groups of fatty acids (FA) [11]. The α-helical N-terminus is 
mandatory for membrane interaction and therefore for overall FA transfer. Apart from the 
FABP classification mentioned above, these proteins can be grouped according to their 
binding abilities. Group 1 (FABP1 and 6) is capable of binding FA and bulky ligands such as 
bile acids, cholesterol and haem. Group 2 (FABP3-5 and 7-9) binds FA, retinoids and 
eicosanoids. Only FABP2 solely binds FA, although in a bent instead of U-shaped 
conformation like groups 1 and 2 [12].  
 
A B  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3D structure of the FABP2 protein viewed from two different angles (A, B). Taken from the 
NCBI structure database viewed via CN3D viewer version 4.1. Red indicates β-strands, blue indicates α-
helixes, arrowheads indicate direction [13]. 
 
Besides passive diffusion across plasma membranes, FA translocation can also be enhanced 
by the fatty acid transport protein (FATP) and plasma bound FABP(PM) [14]. The FA 
dissociation from the plasma membrane into the cytoplasm is increased by cytosolic FABPs, 
which enhance the aqueous solubility of FA [15]. In addition to FABP-mediated increase in 
desorption and cytoplasmic diffusion, FA can interact directly with the phospholipid bilayer 
General introduction – FABP2 
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of acceptor membranes [16, 17]. Besides their function in lipid metabolism, FABPs are 
involved in FA-mediated gene regulation via modification, binding and activation of 
transcription factors (TF), modifying mRNA stability and influencing TF expression [18]. 
One of the most frequently mentioned TF family associated with FA regulation are the 
peroxisome proliferator-activated receptors (PPAR) as their regulative potential can be 
influenced by FABPs [19-21].  
Furthermore, FABPs are relevant for cell growth and proliferation in different tissues [9]. In 
addition, FABP1 showed antioxidative potential in transfected liver cell lines [22]. 
 
The human FABP2 gene (OMIM accession number: 134640; GenBank: NM_000134.3) is 
located on chromosome 4q28-q31, contains 4 exons and codes for a 15.1 kDa protein 
comprising 132 aa [23]. 
FABP2 is expressed in the small intestine together with FABP1 and 6, whereas FABP2 is 
solely found intestinally [24, 25]. The highest FABP2 expression is quantified in the jejunum 
and decreases in the proximal duodenum and colon [23]. Maximum protein abundance is 
detected in the fat absorbing upper villus region, while FABP2 is not detectable in crypt cells 
[26]. The expression of FABP2 is up-regulated simultaneously with cell and tissue 
differentiation [26, 27]. Its expression is increased by FA, hormones and cytokines (e.g. 
butyric acid and oleic acid, insulin, leptin, phosphatidylcholine, hydrocortisone, tumor 
necrosis factor α (TNFα) and peptide tyrosine tyrosine (PYY)), and decreased after exposure 
to epidermal growth factor (EGF) in cell culture [28-30]. Mouse studies revealed an increase 
of FABP2 mRNA after administration of PPARα agonists [31]. Knock out (KO) of 
transforming growth factor β 1 (TGFβ1) or estrogen related receptor α (ERRα) showed down-
regulation of FABP2 [32]. ERRα regulation may indicate a sex specific gene expression 
pattern of FABP2 as seen in FABP2 KO mice. The FABP2 promoters of rat and mouse 
showed cis-binding sites for a CCAAT enhancer binding protein (C/EBP), hepatocyte nuclear 
factor 4 (HNF4) and the apolipoprotein A1 regulatory protein 1 (ARP1) [33]. Influence of the 
TF TGFβ-SMAD/GATA4 on FABP2 promoter activity was also shown in mice [34]. 
Recently, regulation of the FABP2 promoter via the TFs HNF1α and HNF4α was revealed in 
cell culture [35, 36].  
 
FABP2 localization is congruent with its postulated function in absorption, cellular binding 
and trafficking of non-esterified long-chain free FA, which are incorporated into triglyceride 
(TG)-rich chylomicrons for subsequent transport [8, 37, 38]. Although FABP2 seems to be 
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the most important protein of its family in the gut the intestinal expression of FABP1 is 5-fold 
higher compared to FABP2 [39]. This may be due to their different activities. The transport of 
FAs is markedly faster via FABP2 than via FABP1, caused by different mechanisms of 
interaction with acceptor model membranes. Transfer by FABP2 is mediated by protein-
membrane collisional interactions while FAs have to diffuse through the aqueous phase for 
FABP1 binding. This is due to altered integrity of the α-helix of FABP2, which is mandatory 
for membrane interaction (see above) [40]. 
The redundancy of FABP1, 2 and 6 in intestinal cells may contribute to the inconsistent 
results from in vivo and in vitro studies according to FABP2 function. FABP2 overexpression 
in endogenously FABP1 and 2 expressing Caco-2 cells led to reduced fatty acid incorporation 
and secretion but to increased cellular lipid content [29, 41]. Overexpression in human 
intestinal epithelial cell line (HIEC-6) enhanced mitochondrial FA oxidation, cholesterol 
transport gene expression and influenced interaction with nuclear receptors [42]. 
Undifferentiated ES cells stably expressing FABP2 revealed elevated initial and maximal FA 
uptake and cytoplasmatic diffusion [43]. L-cell fibroblasts expressing FABP2 also exhibited 
increased cytoplasmatic diffusion and initial FA esterification into TG as well as elevated TG 
and cholesteryl ester mass [44, 45]. FABP2 KO in mice revealed altered lipid metabolism in 
male animals only [32]. They showed traits of the MetS such as increased body weight, 
elevated plasma insulin and TG. They also showed high fat diet-induced fatty liver although 
altered FABP1 level were not observed [46, 47]. At this, differences in FABP1 and 2 
expressions between mice and humans have to be considered. While FABP2 expression is 
similar, human FABP1 transcript levels are 2.5-fold higher [39].  
 
The FABP2 gene carries a G>A exchange at codon 54 (rs1799883), resulting in an Ala-allele 
and a Thr-allele [48]. This polymorphism has been analysed extensively with divergent 
results. The Thr54 allele has been associated with a variety of traits of the MetS: i) especially 
those concerning the FA metabolism, such as reduced HDL-cholesterol, elevated total and 
LDL-cholesterol, hypertriglyceridemia, increased affinity for long-chain FA, FA flux into the 
circulation and FA oxidation [49-52]; ii) concerning the carbohydrate metabolism, such as 
insulin resistance, increased fasting plasma glucose and fasting insulin [53-55]; iii) and 
concerning inflammation and complex diseases like elevated C-reactive protein (CRP) and 
interleukin 6 (IL6) level, obesity, T2D, CVD, stroke, reduced resting metabolic rate and renal 
diseases [56-59]. In contrast, a number of studies showed no association of the Thr54 allele 
with changes in BMI, total and LDL-cholesterol, hypertriglyceridemia, FA absorption rate, 
General introduction – FABP2 
- 9 - 
lipid or glucose metabolism, insulin resistance, T2D or CVD [50, 58, 60-65]. Third, some 
studies revealed beneficial effects of the Thr54 polymorphism like reduced total and LDL-
cholesterol, reduced total abdominal adipose tissue, lower subcutaneous abdominal fat and 
glucose levels, decreased systolic blood pressure and a later onset of alcoholic cirrhosis [66-
69]. Porcine FABP QTLs were initially also linked to elevated fat mass [9] while recent 
studies with physically mapped markers stated that the FABP cluster was outside this region 
[70]. Divergent results may be caused by different ethnic, phenotypic and lifestyle 
backgrounds of study populations, with varying frequencies of the Ala54Thr polymorphism 
between 18% and 40% [53]. 
Association between FABP2 Thr54 genotypes and reduced insulin sensitivity was increased 
after normalisation for differences in body composition and habitual physical activity (PA) 
levels. Another study showed association of the Thr54 SNP with reduced insulin sensitivity 
only when individuals were consuming a high fat diet [71]. Interaction between the Thr54 
allele, fat composition and consumption was uncovered by Dworatzek et al. They showed that 
Thr54 carrier had increased chylomicron cholesterol but only after administration of olive oil 
[72]. However, Morcillo et al. stated that the Thr54 polymorphism was associated with insulin 
resistance in subjects with a high intake of sunflower oil [73]. Normolipidemic Thr-carrier 
showed increased fasting free FA after a saturated FA (SFA) diet in contrast to homozygote 
Ala-carrier [74]. Furthermore, Thr-carrier had lower glucose tolerance, lower insulin action 
and higher lipid oxidation rates even if they were following a low fat diet [75]. Obese children 
with the Thr54 polymorphism displayed lower arachidonic acid (AA) and delta-6-desaturase 
(D6D) activity in fasting plasma [76]. AA is a pro-inflammatory stimulus, but the positive 
effect of low AA levels on inflammation faces the negative effect of low AA levels in PPARγ 
signalling [77], since AA can act as a ligand for PPARγ, which leads to increased insulin 
sensitivity [78, 79]. Other authors explained the effects on AA and D6D with the type of 
dietary FA ingested and not with the Ala54Thr polymorphism [73].  
Functional analysis in Caco-2 cells transfected with FABP2 bearing the Thr-allele showed 
increased cellular FA transport and TG secretion compared to the Ala-allele [8]. Human 
intestinal explants homozygous for the Thr-allele showed elevated secretion of newly 
esterified TG and chylomicrons versus Ala-allele carrier [37].  
 
Since the FABP2 Ala54Thr polymorphism has been analysed extensively this work focuses 
on the analysis of the FABP2 promoter and its polymorphisms in order to reveal a more 
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precise knowledge about the interaction between FABP2, lipid metabolism and traits of the 
MetS.  
Sequencing studies of the 5´ upstream promoter region of FABP2 showed insertion/deletion 
sites c.-80_-79insT (rs5861422), c.-136_-132delAGTAG (rs5861423) and c.-168_-
166delAAGinsT (rs1973598) as well as SNPs c.-260G>A (rs6857641), c.-471G>A 
(rs2282688) and c.-778G>T (rs10034579). These six variants are in complete linkage 
disequilibrium (LD) resulting in only two haplotypes A>B with an allele frequency of 44% in 
Caucasians [80-82]. The FABP2 promoter haplotype B revealed a protective effect against 
traits of the MetS. It was associated with reduced BMI, lower postprandial TG levels and 
decreased risk for T2D [80, 81, 83]. Prior association studies were carried out in relatively 
small cohorts composed of 100-1000 participants. The first of four papers of this work 
addresses the association of the FABP2 promoter polymorphisms and BMI as a main trait of 
the MetS in a large (n=8072) population-based survey of the KORA study cohort. 
 
 {1} M. Böhme, H. Grallert, M. Klapper, C. Gieger, A. Fischer, I. Heid, H.-E. Wichmann, 
F. Döring, T. Illig, Association between functional FABP2 promoter haplotypes and body 
mass index: Analyses of 8072 participants of the KORA cohort study, Molecular 
Nutrition and Food Research  53 (2009). 
 
Functional analysis of haplotypes showed almost 2- to 3-fold lower transcriptional activity of 
the rare haplotype B compared to haplotype A in Caco-2 cells [83]. This activity difference is 
due to decreased binding affinity of GATA5 and 6 to the c.-80_-79insT polymorphism [84]. 
Recently, a 2-fold higher activity of haplotype B compared to haplotype A was detected by 
Rosiglitazone stimulated PPARγ/RXRα in FABP2 deficient HeLa cells [84, 85]. Accordingly, 
the second paper of this work investigates the functional regulation of the FABP2 promoter 
by Rosiglitazone stimulated PPARγ/RXRα in different cell lines. 
 
 {2} M. Böhme, I. Nitz, F. Döring, M. Klapper, Analysis of the transcriptional 
regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and OCT1, 
Biochim Biophys Acta  1779 (2008) 616-21. 
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The Microsomal Triglyceride Transfer Protein (MTTP) 
The human microsomal triglyceride transfer protein (MTTP, OMIM accession number: 
157147; GenBank: NM_000253.2) is located on chromosome 4q24, contains 19 exons and 
codes for a 97 kDa protein comprising 876 aa residues. It belongs to a family of large lipid 
transfer proteins with orthologs in nematodes, fish, insects and mammals [86]. MTTP 
comprises four structural domains, three β-sheets (N, A, C) and one α-helix. The N-sheet and 
the α-helix are relevant for binding with the N-terminus of apolipoprotein B (apoB), while the 
A- and C-sheet form the lipid transfer/binding domain. Kinetic studies suggest that MTTP has 
two lipid-binding sites. The first site is probably involved in lipid transfer while the second 
site may have a function in membrane association. The membrane association domain, which 
is relevant for lipid droplet formation, consists of N- and A-sheet parts. MTTP affinity for 
apoB increased after lipid association, which implements interdependent domain activities 
[87]. MTTP encodes the large subunit (M subunit) of the heterodimeric microsomal 
triglyceride transfer protein (MTP). Protein disulfide isomerase (PDI, P subunit) completes 
the heterodimer, which plays a central role in lipid transport and lipoprotein assembly.  
 
MTTP is abundantly expressed in the liver and intestine. Other tissues, including 
hematopoietic cells, synthesize less MTTP due to an alternative promoter and exon 1 
(MTTPv1). The exon variation encodes an N-terminal change of 2 aa, while functional 
differences were not observed. The abundance of MTTP in non-apoB-expressing tissues 
seems to be relevant for CD1d activation [88]. However, in adipocytes MTTPv1 is primarily 
localized to the Golgi and therefore may have a distinct role in lipid storage in adipose tissue 
[89]. The MTTP promoter region contains binding sites for the overlapping insulin response 
element (IRS)/sterol regulatory binding proteins (SREBP) and the COUP-TFII. Both TFs 
promote down-regulation. The MTTP promoter is activated by HNF4α, which is essential for 
hepatic expression, HNF1α, LRH1, DR1, as well as PPARα/RXRα and FOXA2. In addition 
to direct interaction of these TFs with cis-regions on the MTTP promoter, regulation via co-
factors and environmental influences was described. PPARγ coactivator 1β (PGC1β) 
enhanced transcription via FOXA2 and RXRα, while the small heterodimer partner (SHP) 
down-regulates MTTP via HNF4α and LRH1 interaction [90]. 
 
While MTP displays orthologs in multiple kingdoms their protein function differs between 
invertebrates and vertebrates [86]. MTP functions in vertebrates are i) lipid transfer activity 
and membrane binding, ii) lipid droplet formation in the endoplasmatic reticulum and iii) 
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apoB binding [91]. During lipid transfer MTP interacts with donor and acceptor vesicles for 
acquisition and delivery. The optimal lipid transfer activity was measured in the presence of 
neutrally charged membranes. Presence of negatively charged lipids in membranes decreased 
the lipid transfer activity of MTP [92]. In hepatocytes MTP was crucial for aggregation of 
lipid droplets and their transport from the cytosol into the Golgi and endoplasmatic reticulum 
(ER). Further, TG content in microsomes was MTP dependent, while phosphatidylcholine 
concentration was independent of MTP [93, 94]. MTP is an essential chaperon for nucleation 
and desorption of primordial apoB-containing lipoproteins with a density under 1.063 g/ml, 
namely chylomicrons, LDL and VLDL [90].  
MTP is involved in immune system signalling via lipidisation of CD1d, which is a major 
histocampatibility complex class 1 homolog presenting lipid and glycoplipid antigens to 
natural killer T cells. MTP directly transfers phospholipids to the antigen binding cleft of 
CD1d in the ER and thereby facilitates rapid cytokine production [95].  
 
The impact of polymorphisms on MTTP promoter activity and protein function were analysed 
comprehensively via association analysis although with contradictory results. Table 1 
summarises association studies between SNPs of the MTTP locus and metabolic traits. The 
polymorphisms studied most extensively are the promoter SNPs c.-493G>T (rs1800591),  
c.-400A>T (rs1800803), c.-164T>C (rs1800804) and the coding SNP I128T (rs3816873). 
These SNPs are summarised based on their nearly complete linkage disequilibrium [96]. In 
different study populations they were associated with reduced, increased or no traits of the 
MetS. Functional analysis of the 128T polymorphism showed reduced thermal stability and 
increased cleavage of MTTP by proteolysis, which indicates a less compact fold and 
structural stability. This impairs apoB binding and, consequently, decreases LDL production. 
Accordingly, a protective effect of the 128T polymorphism and the promoter SNPs is 
postulated [97]. In contrast, a SREBP1a regulation of the MTTP gene via SNP c.-164T>C 
results in a higher activity of the rare C-allele. This promoter activity was synergistically up-
regulated by the rare c.-493G>T polymorphism [98]. Furthermore, three common missense 
polymorphisms (Q95H (g.343G>C), Q244E (rs17599091), H297Q (rs2306985)) were described 
which exhibited no influence on MetS [96]. Another study comprising 9 patients with high 
apoB level and 7 controls were genotyped for polymorphisms in the MTTP gene. 4 out of 11 
SNPs were associated with increased abdominal visceral adipose tissue and LDL-apoB. These 
were the previously described -400T allele, and the homozygote carrier of the new 282G/G, 
933C/C and 1151A/A alleles [99].  
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reference 
middle-aged white American men [100], FH pat. [101], 
white UK men [96, 102], visceral obese and 
hyperinsulinemic Chinese men [103], Chinese TD2 pat. 
[104], T2D pat. [105], healthy German volunteers [106], 
MICK+EPIC [107] 
middle-aged white American men [100], Chinese TD2 pat. 
[104], CARDIA [108], T2D pat. [109], white American 
men [96, 110], NASH pat. [111, 112], SCPSB [113], 
Austrian PAD pat. [114], Japanese women [115], Chinese 
[116], Italian [117], Italian HCV3 pat. [118] 
white American men [110], myocardial infarction pat. 
[119], Framingham Offspring study [120], SCPSB [113], 
French-Canadian youth [62], HCV-pat. [121] 
nonagenarians [122] 
white UK men [96, 123], nonagenarians [124] 
white UK men [96, 123] 
white UK men [96, 123] 
traits 
- reduced total and LDL-cholesterol, VLDL, apoB, TG (only in 
FH women), IDL and LDL production rate, smaller LDL 
particle size, carotic IMT, pp-insulin, dias. blood pressure, T2D 
- increased lipid content of VLDL, total and LDL-cholesterol, 
TG, FFA, apoB, apoB-48, intrahepatic TG (in T2D), plasma 
insulin, BMI, NASH, CHD, PAD, BMD, fibrosis, resistin and 
CRP, fall of HDL-C and apoA1, steatosis (HCV3-pat) 
- no association with plasma lipoproteins (total-, LDL-, HDL-
cholesterol and their lipid mass), TG, apoB and AI, IRS, CHD, 
steatosis (HCV-pat) 
- increased longevity 
- no change in lipids, lipoproteins and anthropometric variables, 
longevity (meta-analysis) 
- no change in lipids, lipoproteins and anthropometric variables 
- no change in lipids, lipoproteins and anthropometric variables 
Table 1. Associations between MTTP SNPs and metabolic traits 
 
polymorphism 
493G>T 
(rs1800591) 
 
c.- 400A>T 
(rs1800803) 
 
c.- 164T>C 
(rs1800804) 
 
I128T 
(rs3816873) 
Q95H 
(g.343G>C) 
Q244E 
(rs17599091) 
H297Q 
(rs2306985) 
Abbreviations used: BMD: bone mineral density, CARDIA: African American men, CHD: coronary hart disease, CRP: C-reactive protein, dias: 
diastolic, FH: familial hypercholesterolemia, HCV: hepatitis C virus, HCV3: hepatitis C virus genotype 3, IMT: intima media thickness, IRS:: 
insulin resistance syndrome, NASH: nonalcoholic steatohepatitis, PAD: peripheral arterial disease, pat: patients, pp: postprandial, SCPSB: Scotland 
Coronary Prevention Study, T2D: type 2 diabetes mellitus  
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The same group found an association between a homozygous c.419-420insA and the dietary 
fat absorption deficiency abetalipoproteinemia (ABL) in a family study [125].  
Expression studies in cell culture with truncated C-terminus MTTP abolished TG transfer and 
deletion of a C-terminal 20 aa residue resulted in ABL [126]. 
 
Since the initial association studies were carried out with small cohorts, the third paper of this 
work investigates the association between MTTP variants and the MetS traits BMI, waist 
circumference and total cholesterol in the large KORA cohort with 7582 participants. For 
comprehensive locus coverage 8 haplotype-tagging SNPs (rs3811800, rs3816873, rs1057613, 
rs2035816, rs982424, rs2306985, rs2903202, rs1491244) comprising 52kb of the MTTP locus 
were examined. 
 
 {3} M. Böhme, H. Grallert, A. Fischer, C. Gieger, I. Nitz, I. Heid, C. Kohl, H.-E. 
Wichmann, T. Illig, F. Döring, MTTP variants and body mass index, waist circumference 
and serum cholesterol level: Association analyses in 7582 participants of the KORA 
study cohort, Molecular Genetics and Metabolism  95 (2008) 229-232.. 
 
 
The Prostaglandin E Synthase 2 (PTGES2) 
The prostaglandin E synthase 2 gene isoform 1 (PTGES2, OMIM accession number: 608152; 
GenBank: NM_025072.4) maps to the chromosomal band 9q34.11, contains 9 exons and 
codes for a 33 kDa protein comprising 377 aa residues. It is required for prostaglandin E2 
(PGE2) production from PGH2. PGE2 is the most common prostanoid of the eicosanoid 
family. It is synthesised from endogenously produced or exogenically supplied semi-essential 
AA, which is converted to PGG2 and PGH2 by cyclooxigenases (COX1 and 2). PGE2 exerts a 
broad range of bioactivities like smooth muscle dilatation/contraction, sodium excretion, body 
temperature regulation, induction of pain, inflammation-associated bone resorption and 
inhibition of immune responses [127]. Beside its considered role as the principal 
prostaglandin in acute inflammation, PGE2 also blocks lipolysis and induces hypertrophy in 
adipose tissue. Furthermore, leptin releasing properties were described [128].  
 
Three PTGES are known. The first is the ubiquitously and constitutivly expressed cytosolic 
(c)PTGES, which is relevant for basal PGE2 production. The second is the inducible 
microsomal or membrane bound (m)PTGES1, which plays a central role in inflammation. 
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Due to this function, mPTGES1 is the PTGES analysed most extensively [129]. Both PTGES 
belong to the membrane-associated proteins involved in eicosanoid and glutathione (GSH) 
metabolism (MAPEG) family, unlike the third PTGES. The third (m)PTGES2 does not 
require GSH for activation, although its activity is enhanced by GSH and other thiol 
compounds. Based on sequence analysis PTGES2 showed a 110Cys-x-x-Cys113 region, which 
is also present in thioredoxin and glutarredoxin. Since PTGES2 activity was abrogated by 
110Cys mutation, it can be assigned to the thioredoxin family [130].  
Three PTGES2 isoforms are known, of which the isoforms 1 is the most abundant. It is 
constitutively expressed in various tissues, including skeletal muscle, kidney, liver and 
adipocytes, were PTGES1 levels are low [131]. Unlike PTGES1, PTGES2 is not induced by 
the pro-inflammatory cytokines IL-1β, TNFα or NF-κB. PTGES2 promoter studies on mice 
showed multiple Sp1 sites and a GC box without a TATA box motif [132]. Interestingly, KO 
of the inflammatorily stimulated COX2 gene in mice decreased PTGES2 expression, while 
PTGES1 expression was unaffected [133]. In an animal model of adjuvant-induced arthritis 
PTGES1 and COX2 level increased, while cPTGES and COX1 level were not altered, as 
described prior for inflammatory diseases. The PTGES2 level slightly decreased [134]. This 
indicates a more basal metabolic function of PTGES2 that is not primarily inflammation-
dependent. 
PTGES2 is identical with the gamma activated transcriptional element (GATE) binding factor 
(GBF1), which is induced by interferon γ (IFNγ). Since IFNγ is a critical cytokine in viral 
infection, PTGES2 may still be involved in disease-related metabolism. Accordingly, 
PTGES2 is up-regulated in a variety of cancers. However, the strong trans-activating activity 
of GBF1 is accompanied by a weak DNA binding property [135]. 
 
Association studies between PTGES2 and MetS traits are limited. Linkage between the 
PTGES2 harbouring chromosomal band 9q34.11 and body weight has been described [136]. 
Three independent study populations showed associations between the PTGES2 R298H 
(rs13283456) polymorphism and reduced risk for T2D [137-139]. The promoter SNP  
g.-417G>T and three haplotype tagging SNPs (rs884115, rs10987883, rs4837240) showed no 
association with traits of the MetS [138]. Association between the R298H and reduced fasting 
insulin, pp-insulin after OGTT and reduced HOMA index disappeared after adjustment for 
BMI, though BMI was only marginally associated with the H-allele [137]. 
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The fourth paper of this work examines if the rare H-allele contributes to BMI changes. 
Therefore, the association between PTGES2 R298H polymorphism and BMI in a large 
(n=8079) population-based survey of the KORA study cohort was analysed. 
 
 {4} A. Fischer, H. Grallert, M. Böhme, C. Gieger, I. Lindner, I. Heid, H.-E. Wichmann, F. 
Döring, T. Illig, Association analysis between the PTGES2 R298H polymorphism and 
body mass index in 8079 participants of the KORA study cohort, Genetic Testing  (2008). 
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General discussion 
 
Genotypic association of the FABP2 promoter haplotypes with BMI 
Few studies have yet carried out association analysis of the FABP2 promoter and traits of the 
MetS. The first paper of this work explores the association of the FABP2 promoter haplotypes 
with BMI, a predominant component of the MetS. All previous studies were conducted in 
small cohorts with an average size of 150 and never more than 1300 people. For the present 
study, the KORA cohort with 8072 participants was used for association examination. 
No association between the FABP2 promoter haplotypes and BMI was found in the study 
population unstratified by gender and in the female subgroup. Male subjects showed a 
significant reduction in BMI of -0.39 BMI units (p=0.02) for the homozygous FABP2 
promoter haplotype B compared with homozygous haplotype A. Male carrier of haplotype B 
(additive model) showed a significant decrease in BMI of -0.19 BMI units (p=0.03). These 
findings were congruent with a significant reduction in BMI of the minor haplotype carrier in 
the BMI point categories of 25-30 (-0.10 BMI units, p=0.03) and <30 (-0.37 BMI units, 
p=0.02).  
 
Significant haplotype differences were only seen after gender stratification and solely for 
male participants. A reduction in BMI of male haplotype B carrier is further evidence for the 
previously stated protective effects of the FABP2 promoter haplotype B against traits of the 
MetS and T2D [80, 81, 83]. Although these results are in contrast to increased BMI in female 
and lack of association with male BMI of non-Hispanics from Colorado (USA) [81]. These 
differences may partly be due to different diet composition, especially FA, as described for 
the FABP2 Ala54Thr polymorphism [72, 73]. Medication is not surveyed in the KORA 
cohort. This may confound results since pharmacologic treatment potentially influences traits 
of the MetS [140]. Additionally, divergent associations of the FABP2 Ala54Thr SNP and the 
FABP2 promoter polymorphisms in various populations may be due to a varying LD [81]. 
The LD (D’ and r²) between the FABP2 promoter haplotype tagging SNP c.-471G>A and the 
Ala54Thr polymorphism were analysed [unpublished] using Haploview 4.0 [141]. Table 2 
shows D’ and r² for the 3 HapMap supported populations CEU (CEPH: Utah residents with 
ancestry from northern and western Europe), YRI (Yoruba in Ibadan, Nigeria) and CHB+JPT 
(Han Chinese in Beijing, China and Japanese in Tokyo, Japan) [142]. Haploview analysis 
revealed maximal LD scores only for the CEU population and solely with the D’ algorithm. 
Calculations with the r² algorithm showed no complete LD in any population of the HapMap 
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project. The complete LD in CEU was not confirmed by a study of Formanack and Baier, 
who found complete LD exclusively in Pima Indians but not in white Americans [82].  
 
Table 2. D’ and r² between the FABP2 promoter haplotype tagging SNP c.-471G>A and the FABP2 
Ala54Thr polymorphism 
population D’ r² 
CEU 1.000 0.491 
YRI 0.926 0.267 
CHB+JPT 0.910 0.559 
Abbreviations used: CEU: (CEPH) population from Utah residents with ancestry from northern and 
western Europe, YRI: population from Yoruba in Ibadan, Nigeria, CHB+JPT: population from Han 
Chinese in Beijing, China and Japanese in Tokyo, Japan 
 
A gender specific phenotype has previously been described in FABP2 KO mice [32], which 
was shown to be associated with elevated body weight, plasma insulin and TG, as well as 
high fat diet induced fatty liver specifically in male mice [46, 47]. It must be admitted that 
this is in contrast to reduced BMI of the in vitro less active FABP2 haplotype B. 
The finding that FABP2 is associated with BMI solely in males is not implausible, since 
different sets of genes influence BMI in men and women. Various studies have shown 
estrogen- and testosterone-specific gene regulation. This highlights the impact of age as a 
confounding factor in association studies. Indeed, a strong age-dependent association with 
obesity has been shown for the gene roundabout axon guidance receptor homolog 1 (ROBO1) 
in several studies [143]. Besides, anatomical and physiological differences between men and 
women in fat distribution, insulin resistance, lipid metabolism and cardiovascular function 
have been described. These gender-dependent variations can result in a sex-specific 
phenotype [144], albeit gender-dependent and haplotype specific FABP2 regulation awaits to 
be functionally examined.  
One possible regulative pathway may act via PPARγ. Paper {2} shows increased haplotype B 
activity after Rosiglitazone stimulated PPARγ/RXRα administration. Animal models revealed 
higher PPAR activity in male mice compared to females [145, 146]. This may lead to a larger 
activity range of ectopic expressed FABP2 haplotype B, which results in a more distinctive 
effect on metabolic traits. 
A positive effect of increased haplotype B activity may be the regulation of the glucagon like 
peptide 1 (GLP1). FABP2 may not be expressed solely in enterocytes but also in GLP-
expressing intestinal epithelial L-cells [Klapper, M, personal communication]. Despite its role 
in insulin und glucagon homeostasis GLP1 increases satiety [147]. Carriers of a more active 
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FABP2 haplotype are able to transport higher amounts of FA, which increase GLP1 
expression resulting in earlier satiety. A gender-specific influence may exist, since GLP1 
levels are lower in males [148]. Hence, haplotype-specific regulation may have more impact 
on low male GLP1 levels than on high female levels. In future studies FABP2 and GLP1 
expression in genotyped males and females has to be analysed for validation of these 
hypotheses. 
 
Paper {1} revealed a reduced BMI for non-obese but not for obese males carrying haplotype 
B. Hence, the FAPB2 promoter haplotype B has a protective effect against overweight only as 
long as obesity has not occurred. 
Men with increased BMI had more intra-abdominal adipose tissue than visceral adipose tissue 
compared to females [149]. Intra-abdominal fat is associated with increased plasma TG, 
fasting glucose, postprandial insulin, free FA and blood pressure, as well as with an increase 
in pro-inflammatory cytokines like TNFα, NF-κB or IL6 [149-151]. Obesity is further 
associated with an increase in the LDL atherosclerosis marker lipoprotein(a) in men but not in 
women [152]. The increase in several metabolic risk factors in obese men may abolish the 
positive effect of the FABP2 haplotype B observed in normal weight men.  
 
In conclusion, the first paper of this work shows association of the FABP2 promoter 
haplotype B with reduced BMI but only in normal weight males.  
 
 
Functional analysis of FABP2 promoter haplotypes 
Several studies which have analysed the distribution of polymorphisms found that functional 
SNPs occur in 30-60% of human promoters. They tend to cluster in close proximity, around 
100 bp upstream, to the transcription start site. These data indicate that promoters may 
represent a major site where polymorphisms contribute to human disease [153].  
Search for polymorphisms in the FABP2 promoter revealed six polymorphic sites altering the 
transcriptional activity of FABP2, which were associated with traits of the MetS [80, 81, 83]. 
Genome wide linkage scan revealed an association of the FABP2 locus with physical fitness 
in dizygotic female twins [154] but lacked MetS association [155-157]. A 2- to 3-fold lower 
activity of FABP2 promoter haplotype B in post-confluent Caco-2 cells is caused by 
decreased binding affinity of GATA5 and 6 to the c.-80_-79insT polymorphism [84]. 
Additionally, FABP2 deficient HeLa cells exhibited a 2-fold higher activity of haplotype B 
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than A by Rosiglitazone stimulated PPARγ/RXRα [85]. Here, a PPARγ binding site at 
position -623/-607 of the FABP2 promoter was identified via in silico analysis and electro 
mobility shift assays (EMSA). Since haplotype specific binding of PPARγ to the FABP2 
promoter was not observed this cis-acting element for PPARγ can not solely account for 
haplotype specific regulation. Interaction with one or more TFs seems likely.  
Polymorphism c.-471G>A was involved in determining different FABP2 promoter haplotype 
activities. However, reversal of the mutation in the opposite haplotype did not abrogate 
PPARγ inductivity. More precise investigation of the region comprising polymorphism -471 
via in silico and EMSA analysis revealed an octamer-binding TF 1 (OCT1) binding site. 
Transfection of OCT1 induced FABP2 promoter activity by a factor of three without 
haplotype specific variation. The different FABP2 promoter haplotype activities after 
Rosiglitazone stimulated PPARγ/RXRα transfection were abolished after co-transfection with 
OCT1. Thus, high concentration of OCT1 can override the effect of PPARγ/RXRα on 
different activities of FABP2 promoter haplotypes. 
 
PPARγ promotes the expression of FABP1 and 4 [158], albeit the relevance for Rosiglitazone 
dependent PPARγ/RXRα regulation of the FABP2 promoter haplotypes has to be considered 
carefully. In vivo FABP2 is present in the small intestine [23] where PPARα and PPARδ, but 
not PPARγ, are predominantly expressed [159]. The higher activating potential of FABP2 
promoter haplotype B by PPARγ might result in an ectopic expression of FABP2 in PPARγ 
expressing tissues of haplotype B carriers. PPARγ was associated with T2D and obesity [155-
157]. Therefore, FABP2 may exhibit its influence on the MetS via PPARγ specific ectopic 
regulation.  
 
The ubiquitously expressed OCT1 plays a central role in metabolic homeostasis [160, 161]. 
However, the OCT1 dependent up-regulation of FABP2 promoter constructs in HeLa cells 
could not be confirmed in intestinal cells. Transfection of OCT1 in Caco-2 cells showed no 
effect on FABP2 mRNA level. Even if OCT1 seems not to be relevant for intestinal FABP2 
expression, it may contribute to an ectopic expression of FABP2 in tissues with high OCT1 
expression like prostate, cortex or lymphocytes [25]. A interdependence between 
PPARγ/RXRα and OCT1 can be present either via direct binding of RXR with OCT1 [162], 
as well as via induction of OCT1 expression by PPARγ [163]. 
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Figure 2 discloses a working model for the interaction between TFs and the FABP2 promoter 
in HeLa cells. PPARγ binds at position -623/-607 and drives haplotype specific activation via 
interaction with a hypothetical HeLa cell specific TF (TFH1). TFH1 binds to the promoter 
region around SNP c.-471G>A in a haplotype specific manner. The complex is stabilised by 
RXRα and Rosiglitazone (Rosi). This results in haplotype specific promoter assay activity 
(Fig. 2A). Co-transfection with OCT1 abolishes haplotype specific TFH1 binding. Since 
OCT1 increased neither FABP2 mRNA levels {2} nor luciferase promoter plasmid activity in 
Caco-2 cells [unpublished], PPARγ/RXRα/OCT1 derived activity in Hela cells seems to be 
regulated by another factor (TFH2) (Fig. 2B).  
 
 
Figure 2. Working model for the HeLa cells specific TF binding to FABP2 promoter haplotypes A and B 
after transfection with Rosiglitazone (Rosi) stimulated A) PPARγ/RXRα and B) PPARγ/RXRα/OCT1. 
TFH1/2 abbreviates hypothetical HeLa cell specific TFs. White bars indicate basal activity of luciferase 
promoter constructs. Black bars show promoter activity after induction with Rosi. N=3, +SD. Refer to text 
for detailed explanation and to {2} for transfection procedures. 
 
Identification of TFH1 and 2 candidates is not trivial. TFH1 has to be a TF interacting with 
PPARγ and/or RXRα and competing with OCT1 for binding sites. PPARγ activity and 
interaction is diverse, ranging from ligand independent transcriptional enhancer function to 
inhibition of gene activity, incorporated in a multifactor complex comprising several co-
factors and ligands. One TFH1 candidate may be NF-κB, since PPARγ interacting properties, 
as well as overlapping binding sites with OCT1 were described for the CRP promoter [159, 
164]. Overlapping with an OCT1 binding site and PPARγ co-factor activity was also shown 
for AP1 on the IL5 promoter [165]. Interestingly, basal NF-κB and AP1 activity in HeLa cells 
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was enhanced by TNFα administration [166]. This may indicate an enhanced ectopic activity 
of FABP2 haplotype B in diseases associated with an increased inflammation status, leading 
to an adverse feedback effect. FA induce NF-κB and TNFα via elevated ROS production 
[167]. Increased NF-κB and TNFα may enhance FABP2 expression which elevates FA 
transport. At this, it has to be considered that PPARγ negatively influences the production of 
inflammatory cytokines such as TNFα and may slow down the self-enhancing FA-ROS-
cytokine-FABP2-FA loop [159]. However, a putative up-regulation of the FABP2 haplotype 
B in inflammation may be in contrast to a higher haplotype A activity in healthy individuals 
anticipated from expression in Caco-2 cells. This has to be taken into account when recruiting 
patients for association studies. 
Furthermore, the silencing mediator of retinoid and thyroid receptor (SMRT) regulates 
transcription of the oxidised LDL receptor together with PPARγ/RXRα. SMRT may be a 
candidate for TFH2, since binding of OCT1 with SMRT was shown in COS-7 cells. A second 
candidate interacting with PPARγ and OCT1 is the ubiquitously expressed C/EBPβ [159]. So 
far, SMRT [168] and C/EBPβ [169] have been described as transcriptional repressors, which 
is contrary to the activation seen in HeLa cells. Additionally, C/EBPβ may be a TFH1 
candidate, since transcriptional interference of OCT1 and C/EBPβ was described for the 
androgen receptor [170]. Another interesting TFH2 candidate may be the ubiquitously 
expressed and in cancer up-regulated signal transducer and activator of transcription 3 
(STAT3). Promoter assays revealed that the α2-macroglobulin promoter is activated only in 
the presence of STAT3, even if an enhanceosome, which comprises OCT1 transactivation, is 
associated with the promoter region [171].  
 
In conclusion, paper {2} revealed haplotype specific activation of the FABP2 promoter by 
PPARγ. A PPARγ binding site at position -623/-607 was identified. Haplotype specific 
activity is controlled via polymorphism c.-471G>A. This polymorphic site revealed no 
PPARγ but OCT1 binding. Even if OCT1 induces the FABP2 promoter, it lacks haplotype 
specific activity. These effects were solely observed in HeLa cells but not in Caco-2 {2} and 
HepG2 cells [unpublished].  
To elucidate the haplotype specific regulation of the FABP2 promoter via PPARγ/RXRα and 
OCT1 ChIP analysis should be carried out for both haplotypes in HeLa and Caco-2 cells to 
reveal TFH1 and 2 candidates. Furthermore, it would be interesting to measure FABP2 
mRNA and protein abundance in intestinal and adipocyte biopsies from homozygous 
haplotype A and B carriers for clarification of putative ectopic expression. 
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Genotypic association of the MTTP H297Q polymorphism with BMI, waist circumference and 
total cholesterol 
More than four million SNPs have been indentified in coding and non-coding regions of the 
human genome, occurring roughly every 100 to 1000 bp [153, 172]. To account for genetic 
variety of the MTTP locus, the third paper of this work displays association analysis with 
BMI, waist circumference and total cholesterol of 7 htSNPs and 2 non-synonymous cSNPs of 
a 52 kb MTTP locus region in the KORA cohort. 
Multiple studies showed associations of the c.-493G>T, c.-400A>T, c.-164T>C and I128T 
SNPs and diverse traits of the MetS leading to contradictory results [96]. All studies were 
conducted in small cohorts with no more than several hundred participants. The KORA cohort 
with 7582 MTTP genotyped participants exhibits no association with the I128T 
polymorphism and BMI, waist circumference or plasma lipids. Functional analyses of the 
promoter polymorphisms and the I128T SNP displayed a combination of a high promoter 
activity with low protein functionality and vice versa [97, 107]. The resulting consequence of 
these opposing effects seems to be a neutral phenotype. 
Surprisingly, the hitherto inconspicuous H297Q polymorphism revealed association to MetS 
traits. Stratification for gender revealed that the general reducing effect of the Q-allele in BMI 
(Q-carrier: -0.18 BMI unit, p=0.01; Q/Q: -0.43 BMI units, p=0.01), waist circumference  
(Q-carrier: -0.45 cm, p=0.01; Q/Q: -0.99 cm, p=0.01) and total cholesterol (Q-carrier: -0.04 
mmol/l, p=0.03; Q/Q: -0.10 mmol/l, p=0.01) is caused by alterations in the female subgroup. 
Only females carrying the Q-allele showed a decrease in BMI (Q-carrier: -0.26 BMI unit, 
p=0.02; Q/Q: -0.66 BMI units, p=0.01), waist circumference (Q-carrier: -0.66 cm, p=0.01; 
Q/Q: -1.44 cm, p=0.01) and total cholesterol (Q-carrier: -0.05 mmol/l, p=0.03; Q/Q: -0.11 
mmol/l, p=0.03).  
 
In silico analysis of the His to Gln exchange at position 297 with Protean (DNAstar-
Lasergene 7.0) revealed a slightly less charged and more hydrophobic MTTP protein 
[unpublished]. Position 297 is located in a domain relevant for lipid binding. This suggests 
increase in lipid acquisition which may lead to faster chylomicron and VLDL maturation in 
Q-allele carrier. This is consistent with observations of fat malabsorption, hepatic steatosis 
and insulin resistance in MTTP loss of function patients and KO mice [93, 96]. 
Conversely, a decrease in delivery and, hence, a retarded lipoprotein maturation is 
conceivable. This hypothesis may be more congruent with reduced total cholesterol levels. 
Cholesterol is transported to the periphery via chylomicrons, VLDL and LDL, whereby 
General discussion – MTTP 
- 24 - 
MTTP is relevant for the assembly of these lipoproteins [173]. A second function of MTTP is 
lipid transport. A delay in TG transport may lead to decreased delivery of TG to the periphery 
especially the abdominal adipose tissue resulting in reduced waist circumference and overall 
BMI. 
 
Associations with the MTTP 297Q allele were solely found in women. A female-specific 
more active rare -493T showed lower TG, VLDL, LDL levels and blood pressure [101, 174, 
175]. Contrary, 128T allelic T2D men from the EPIC study were associated with reduced 
waist circumference and BMI. This was not observed in women from the EPIC cohort [107]. 
Since MTTP and apoB are forming a complex, protein interactions have to be considered. It 
has been shown that apoB mRNA and protein levels are higher in females [176, 177]. Hence, 
H297Q dependent MTTP activity may exhibit more pronounced effects in females than in 
males resulting in a larger phenotype change. 
 
Based on functional associations, the c.-493G>T, c.-400A>T, c.-164T>C and I128T SNPs 
might have an overall neutral effect. This work revealed a strong impact of the H297Q SNP 
on lipid metabolism. Hence, it is debateable if former associations were caused by the H297Q 
polymorphism due to random linkage, rather than evoked by the I128T or promoter SNPs. 
This would explain contradictory study results mentioned above. 
Future studies should analyse H297Q haplotype specific MTTP levels in males and females to 
reveal functional impact of this polymorphism. 
In conclusion, the third paper of this work shows a new association of the MTTP H297Q 
polymorphism with a strong MetS phenotype. Female Q-carrier showed lower BMI, waist 
circumference and total cholesterol. Accordingly, re-analysis of prior associated loci can still 
be important to find new candidates for complex diseases. 
 
 
Genotypic association of the PTGES2 R298H polymorphism with BMI 
Prior studies revealed association of the PTGES2 R298H polymorphism with T2D. To 
elucidate a BMI mediated influence on T2D the R298H and 3 htSNPs comprising a 20 kb 
region of the PTGES2 gene were analysed in 8079 participants of the KORA cohort. 
No association to BMI was found for the 3 htSNPs as well as for females heterozygous for the 
298H allele. Only males heterozygous for the R298H polymorphism showed association with 
reduced BMI (R/H: -0.30 BMI units, p=0.02). This was confirmed by haplotype analysis. 
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Only a 298H containing haplotype showed a significant decrease of BMI in males (-0.19 BMI 
units, p=0.04) but not in females. Homozygous H-allele carrier displayed no association. 
 
A protective effect of the rare H-allele was described for T2D, impaired glucose tolerance, 
fasting and postprandial insulin levels, HOMA indices and insulin resistance [137-139]. The 
fourth paper stated a BMI lowering effect of the H-allele but solely in heterozygous males.  
Hypothesis generation for a H-allele dependent phenotype remains challenging, since the 
functions of PGE2 are diverse. PTGES2 forms homotetramers for enzymatic activity. The 
R298H SNP is located in the homotetramer forming region which may result in altered 
enzymatic activity [130]. A heterozygous genotype might lead to a slight decrease in overall 
PTGES2 function causing a small reduction of PGE2 level. PGE2 possesses anti-lipolytic 
activity and induces adipocyte hypertrophy, hence a reduced PGE2 level may result in a lower 
BMI [178-180]. Assuming that PTGES2 homotetramer formation is abolished or highly 
impaired in homozygous H-allele carrier, the lack of BMI reduction may be due to 
(over)compensatory up-regulation of other PTGES enzymes. Indeed, PGE2 level were 2-fold 
increased in male but not in female homozygous H-allele carrier. However, a heterozygous 
phenotype showed no reduction of PGE2 [181]. 
 
Gender dependent haplotype specific activity of PTGES2 is not reported until now. It was 
stated that PTGES genes are regulated via PPARγ [182]. A sex specific expression profile of 
PPARγ was shown earlier [145]. Further, a putative estrogen binding site in the PTGES2 
promoter was examined via in silico analysis [181] while promoter studies are lacking. 
 
The IFNγ induced trans-activating activity of PTGES2 might be influenced by the R298H 
polymorphism [135]. Promoter studies with both haplotypes showed only a low activating 
potential without a haplotype specific pattern [181]. 
 
Even if the H-allele exhibits only a small impact on overall obesity and BMI, it may 
contribute to a risk reduction of T2D and traits of the MetS. Future studies should analyse the 
gender-specific expression of the PTGES genes for the various haplotypes.  
In conclusion, the fourth paper revealed that the PTGES2 R298H SNP is associated with 
lower BMI in males.  
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Outlook 
Understanding the functional regulation of complex outcomes is demanding as seen for the 
FABP2 promoter haplotypes. Often different studies reveal opposing results. In addition to 
candidate gene approaches current research focuses on genome-wide association studies 
(GWA) to find genes with strong disease association [183]. The most consistently identified 
genes associated with MetS traits via GWA were transcription factor 7-like 2 (TCF7L2) for 
T2D [184], the fat mass and obesity associated gene (FTO) for obesity [185] and the pro-
inflammatory cytokine lymphotoxin-alpha (LTA) for CVD [186]. One of the most discussed 
candidate genes associated with several traits of the MetS are PPARγ [187-189] as well as the 
melanocortin 4 receptor (MCR4) [190]. 
The emerging field of GWA studies failed to show association between FABP2, MTTP or 
PTGES2 and traits of the MetS [184-189]. To address these apparent contradictory results, 
one has to look more carefully at GWAs. First, investigated traits like obesity are considered 
as “complex” but GWAs often associate only one SNP or cluster with specific “complex” 
traits. Second, assuming that these SNPs are the genetic markers with the strongest impact, 
they should be replicated in other GWAs. Indeed, this was only feasible for a few SNPs in 
diverse traits. Third, the functionality of the associated gene has to be taken into account since 
the most extreme p-value alone is not an adequate predictor of true effects [191]. And fourth, 
genes identified by GWAs tend to exert the largest effects, but account only for 5-10% of the 
trait variance. The majority will be more difficult to identify. This becomes apparent on traits 
like blood pressure which failed to show GWA associations [190]. 
Beyond, GWAs are far from representing the whole genome. Analysis of 3 current genome 
wide chips, 500k (Affimetrix) and HumanHap300/550 (Illumnia), revealed low coverage 
especially for singleton SNPs. Singleton SNPs are SNPs that can not be predicted by other 
SNPs via linkage analysis and therefore expanding the chip costs disproportionately. 
Singleton SNPs are significantly more frequent non-synonymous, splicing site, 5’ or 3’UTR 
than intronic or intergenic SNPs. This ascribes them a potentially higher functional 
importance. The tested arrays account only for ~50% of known singleton SNPs. [172]. New 
GWA arrays incorporate copy number variations (CNV) in their design, since CNV 
contribute considerably to disease traits. Admittedly, currently available arrays miss at least 
20% of known CNVs [192]. With decreasing chip costs this coverage will increase in the 
future but has to be considered when interpreting published results. 
With lower costs and higher datasets of GWAs, data analysis will play the most decisive role 
in the future. GWAs reveal many candidates associated with slight phenotype changes, which 
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are per se significant, while after multiple testing these candidates are declared as false 
positives. A GWA of 6148 Sardinians showed association with obesity of the FTO gene but 
not of FABP2, MTTP or PTGES2. A more detailed examination of the dataset revealed 
association of FABP2 with BMI (-0.10 BMI units, p=0.03), hip circumference (-0.11 cm, 
p=0.01) and weight (-0.08 kg, p=0.03) prior to multiple testing. MTTP was analysed but 
showed no significant associations, while PTGES2 was not examined [193]. Hence, GWAs 
give more insights into genetic associations, but their results still have to be carefully studied. 
Further, lack of prior associations in GWA between FABP2 and MetS traits are not 
contradictory, since most GWAs barely account for gender stratification [144]. In accordance, 
paper {1} shows association only in the male subgroup but not within the whole study cohort. 
 
Table 3. Association analysis of FABP2 promoter polymorphism and the MTTP H297Q SNP with BMI 
Genotype Frequencies (n) Unit change in BMI in kg/m2 [95% confidence interval] (p values) 
FABP2 
promoter 
MTTP 
Q297H All Men Wom.  All Men Women 
         
11 11 1052 515 537  1 1 1 
12+22 11 2049 1055 994  0.04 [-0.28,0.36] (0.81) 
0.01 [-0.39,0.40] 
(0.98) 
0.10 [-0.41,0.60] 
(0.70) 
11 12+22 1462 695 767  -0.02 [-0.38,0.33] (0.90) 
0.14 [-0.32,0.60] 
(0.55) 
-0.17 [-0.70,0.37] 
(0.53) 
12+22 12+22 2995 1491 1504  -0.02 [-0.54,0.07] (0.13) 
-0.30 [-0.68,0.31] 
(0.11) 
-0.16 [-0.64,0.31] 
(0.51) 
22 22 174 80 94  -0.91 [-1.61, -0.2] (0.01) 
-0.82 [-1.75, 0.11] 
(0.08) 
-0.99 [-2.02, 0.05] 
(0.06) 
FABP2 promoter (rs6857641), MTTP Q297H (rs2306985) 
 
One advantage of GWA is the possibility to rapidly find potential gene-gene interaction 
candidates, which needs more preliminary results in candidate gene approaches. Since male 
carrier of the FABP2 promoter haplotype B and female MTTP H297Q SNP carrier both 
displayed reduced BMI in the KORA cohort a combined gene-gene interaction association 
analysis was carried out [unpublished]. Unlike anticipated, no significant association of the 
common genotype against one or both rare genotypes was present after gender stratification 
or in heterozygous individuals. Only unstratified homozygous carrier of both rare 
polymorphisms exhibited a BMI reducing effect (-0.91 BMI unit, p=0.01) (Table 3). The 
borderline significance in the gender subgroups (males: -0.82 BMI units, p=0.08; females:  
-0.99 BMI units, p=0.06) may be caused by too small subgroups (males: n=80; females: 
n=94). In conclusion, even if strong phenotypes could be confirmed, results from 
polymorphism specific regulations can not simply be summarised. 
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For understanding the complexity of the MetS GWAs will not be the spearhead in life science 
research. Future investigators will use system based approaches, consisting of GWAs and 
mass spectrometry in combination with computational and statistical tools leading to 
genomic-metabolomic-networks [190]. 
 
A genomic-metabolomic network needs to incorporate environmental factors into data 
interpretation to enhance result quality. While environment includes numerous variables, 
which could not completely be accounted for, interaction with nutrition and particularly fat is 
of special interest for the present candidate genes.  
Independent of the total amount, the type of dietary fat became more important during the 
past few years. The initially recommended <30% of total energy from fat, 2.5% Ω6 and 0.5% 
Ω3 FA [194] is subdivided into <7% from saturated fat (SFA), minimal trans fat (TFA) and 
<200mg/d cholesterol. Multiple dietary intervention studies demonstrated beneficial effects of 
monounsaturated FA (MUFA) and polyunsaturated FA (PUFA) for insulin sensitivity [195]. 
Interestingly, in animal models MUFA substitution of SFA was not atheroprotective per se 
indicating a more complex FA interaction pattern [196]. The pro-inflammatory potential of 
Ω6 as well as the anti-inflammatory potential of Ω3 PUFAs is well established [197], 
nevertheless, the Ω3-ascribed protective effect against T2D was not confirmed in meta 
analysis [195]. SFA level >15% of daily energy intake are associated with adverse metabolic 
effects. When provided moderate and balanced with PUFAs SFAs showed lipogenic, amid 
linkage, bioavailability enhancing, PUFA precursor, cancer prevention and apoptosis 
initiating characteristics ascribing SFAs new and important cell regulatory functions [198].  
Nevertheless, dietary fat intervention studies are numerous with different study settings 
leading to divergent but often well examined outcomes. Some individuals are relatively 
insensitive (hypo-responders) to dietary intervention, whereas others (hyper-responders) show 
enhanced sensitivity [195]. This may partly be due to polymorphisms in fat metabolism 
genes. Variation in dietary fat-dependent gene regulation was stated earlier for the FABP2 
polymorphisms [71-76], while SNP specific nutrigenetic interaction for MTTP shows no 
associations [199] and for PTGES2 awaits elucidation. In general, FABP2 and MTTP 
influence gene regulation via FA regulated TFs which increase transcription of FA 
transport/metabolism and gluconeogenesis genes but also reduce FA oxidation and 
carbohydrate processing genes [18, 167]. While PUFAs regulate transcription via PPARs and 
SREBP, SFAs strongly elevate PGC1β, interact with HNF4, NF-κB, C/EBP and PPARα 
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[198]. PUFA (Ω6) mediated gene regulation is further influenced by PTGES2 which is 
relevant for AA processing [200]. 
Depending on the variety of dietary composition and its influence on gene regulation there are 
still numerous possibilities to perform candidate gene and GWA analysis. 
 
In summary, association analysis in the KORA cohort with more than 8000 participants 
revealed association between BMI and polymorphisms of the FABP2 promoter and the MTTP 
and PTGES2 genes. The MTTP SNP H297Q and related haplotypes are also associated with 
waist circumference and total cholesterol. Functional analysis exhibited, that the FABP2 
promoter haplotype B is 2-fold more inducible by PPARγ/RXRα than haplotype A. This 
difference is caused by polymorphism c.-471G>A. In addition, OCT1 was identified as a TF 
regulating the FABP2 promoter. In conclusion, variants of the FABP2, MTTP and PTGES2 
genes, which are involved in fat metabolism, contribute to the development of the MetS. 
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Association between functional FABP2 promoter
haplotypes and bodymass index: Analyses of 8072
participants of the KORA cohort study
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Studies in relatively small cohorts provide preliminary evidence that functional fatty acid binding pro-
tein 2 (FABP2) promoter haplotypes are associated with type 2 diabetes and BMI. Here, we studied
the influence of the haplotypes on BMI by using 8072 male and female participants of the Koopera-
tive Gesundheitsforschung in der Region Augsburg (KORA) cohort. By linear regression analysis, we
found in males a reduction of –0.39 BMI units (95% CI: –0.73, –0.05, p = 0.024) in homozygous
FABP2 promoter haplotype B carriers. Carriers of haplotype B showed a significant decrease in BMI
of –0.19 BMI units (95% CI: –0.35, –0.02, p = 0.027). In accordance, a significant reduction in
BMI of the minor haplotype carriers in the BMI point categories of 25–30 (BMI units: –0.10, 95%
CI: –0.18, –0.01, p = 0.03) and a30 (BMI units: –0.37, 95% CI: –0.67, –0.07, p = 0.02) were
found. In summary, the minor FABP2 promoter haplotype B contributes to a reduced BMI in men.
This provides evidence that functional FABP2 contributes to multifactorialy regulated body weight.
Keywords:BMI / FABP2 gene / KORA / Promoter polymorphism /
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1 Introduction
The human fatty acid binding protein 2 (FABP2) gene
(FABP2, NM_000134.2) is exclusively expressed in the
intestine during development and cell differentiation in
absorptive cells of the upper villus region [1–3]. Although
the specific function of FABP2 is still not fully elucidated,
the protein is proposed to be involved in fat absorption by
binding and intracellular transport of newly absorbed non-
esterified long-chain free fatty acids, which are finally
assembled and secreted in triglyceride-rich chylomicrons
[4, 5]. FABP2 also mediates fatty acid signalling by trans-
ferring fatty acids to the nucleus as ligands for transcription
factors, such as peroxisome proliferator-activated receptors
(PPARs) [6, 7] and seems to be involved in regulation of
cell proliferation and differentiation [8, 9]. More recently,
an antioxidant function was shown [10, 11].
Based on a huge number of association studies in differ-
ent human populations, FABP2 is described as a candidate
gene for the metabolic syndrome [12–16]. Sequencing
studies [13, 14, 16] revealed that the 59 upstream promoter
region of FABP2 contains insertion/deletion sites c.–80_-
79insT (rs5861422), c.–136_-132delAGTAG (rs5861423)
and c.–168_-166delAAGinsT (rs1973598) as well as c.–
260G A A (rs6857641), c.–471G A A (rs2282688) and c.–
778G A T (rs10034579) single nucleotide polymorphisms
(SNPs). For explanation of sequence variation nomencla-
ture refer to den Dunnen and Antonarakis, 2000 [17]. These
six variants are in complete linkage disequilibrium result-
ing in only two haplotypes A A B. As demonstrated by us
[16] and others [14] the rare FABP2 promoter haplotype B,
with an allele frequency in Caucasians of 44% [16], showed
almost 2–3-fold lower transcriptional activity than haplo-
type A in Caco2 cells. Recently, we showed that this differ-
ent activity is due to decreased binding affinity of GATA-5
and -6 to the c.–80_-79insT polymorphism [18]. The
FABP2 promoter haplotypes were associated with postpran-
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dial triglyceride levels [15], type 2 diabetes [16] and BMI
[13]. Since, these studies were done in relatively small
cohorts composed of 500–1000 participants and functional
intervention studies are still lacking, the associations
remain disputable. In the present study, we analysed the
data of a large (n = 8072) population-based survey from
1994 to 2001 of the Kooperative Gesundheitsforschung in
der Region Augsburg (KORA) study cohort regarding the
association between FABP2 promoter haplotypes and BMI.
2 Materials andmethods
2.1 Study population
In the Southern German region of Augsburg including the
city of Augsburg and the two surrounding counties, popula-
tion-based surveys of the 25–74 years old population in
groups of age range of 5 years were implemented in 1984 as
part of the WHO multinational MONItoring of trends and
determinants in CArdiovascular disease (MONICA) project
and continued since, 1996 within the KORA platform. The
aims of the surveys were to describe the prevalence of com-
mon diseases and their risk factors in a representative sam-
ple of the adult general population. The current study
included the survey of the years 1994–1995 (MONICA S3)
including 4856 participants and the survey of the years
1999–2001 (KORA S4) including 4261 participants yield-
ing 9117 recruited participants. The study population of S3
and S4 consisted of all German residents of the Augsburg
region who were born between 1920 and 1975 identified
through the public record office. More than 99.5% of the
participants were Caucasian. The high standards of the
WHO MONICA project applied to both surveys. All study
participants underwent a standardized interview, a physical
examination and blood withdrawal by trained staff and
signed a consent form of the Bavarian Ethics committee
and the Ethics committee of the University of Munich. For
determination of body weight and height, participants were
asked to remove shoes and heavy clothing. The weight
measurements were done with a calibrated body weight
scale (SECA 709) and were carried out with an accuracy of
0.1 kg. The body height was read to the nearest 0.5 cm on a
body height scale. BMI (kg/m2) was calculated as weight in
kilograms divided by height in square meters. The pooled
data analysis included 8072 individuals with complete
information on age, sex, BMI and genotypes. The range of
BMI was 14–57 kg/m2 and the gender distribution was
equal. There was no overlap between the two surveys by
design. Detail characteristics of the study cohorts were
described elsewhere [19, 20].
2.2 Genotyping
The 59 upstream promoter region of FABP2 containing
insertion/deletion sites c.–80_-79insT (rs5861422), c.–
136_-132delAGTAG (rs5861423) and c.–168_-166delAA-
GinsT (rs1973598) as well as c.–260G A A (rs6857641),
c.–471G A A (rs2282688) and c.–778G A T (rs10034579)
is in complete linkage disequilibrium resulting in only two
haplotypes A A B. FABP2 promoter haplotypes were geno-
typed based on htSNP c.–260G A A (rs6857641) using a
MALDI TOF MS system (Sequenom, Mass EXTEND, San
Diego, USA), with the 59 Capture Primer ACGTTGGAT-
GAACAATCTTCAGACGGCATG and the 39 Capture Pri-
mer ACGTTGGATGTGAGAAGCATACCTATTCTG.
2.3 Statistical methods
We used a linear regression model with BMI as continuous
outcome for both studies combined; the unit change in BMI
by the DNAvariants was estimated. Haplotype analysis was
carried out with the statistical software R (V. 2.3.1. includ-
ing haplo.stats package) using the haplo.glm procedure.
This procedure performs an iterative two-step estimation-
maximization (EM)-algorithm, with the posterior probabil-
ities of pairs of haplotypes per subject used as weights to
update the regression coefficients, and the regression coef-
ficients used to update the posterior probabilities. Haplo-
types were included into the regression model all at once
except the most common haplotype. Using the expected
number of copies of haplotype implies an additive model
for each haplotype. Statistics were gender-stratified
because sex-specific associations of FABP2 polymor-
phisms were described [21, 22].
3 Results and discussion
As shown in Table 1, in the whole study population as well
as in female subjects no associations between FABP2 pro-
moter haplotypes and BMI were found. In male subjects,
we observed a significant reduction in BMI of –0.39 BMI
units (95% CI: –0.73, –0.05, p = 0.024) for the homozy-
gous FABP2 promoter haplotype B compared with homozy-
gous haplotype A (wild type). Carriers of haplotype B
(A/B + B/B) showed a significant decrease in BMI of –0.19
BMI units (95% CI: –0.35, –0.02, p = 0.027). These find-
ings were congruent with a significant reduction in BMI of
the minor haplotype carriers (A/B + B/B) in the BMI point
categories of 25–30 (BMI units: –0.10, 95% CI: –0.18,
–0.01, p = 0.03) and a30 (BMI units: –0.37, 95% CI:
–0.67, –0.07, p = 0.02).
The presented analysis of 8072 participants confirmed
and extended previously data in humans that the rare
FABP2 promoter haplotype B has a protective effect on
metabolic traits like type 2 diabetes [16]. Though, previ-
ously an increase in BMI was found in female non-His-
panics from Colorado (USA) [13] and no decrease in male
whites similar to our results. These differences may partly
be due to different diet composition, especially fatty acids,
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in the two cohorts. Additional, neither this nor the study
from Damcott et al. 2003 [13] were adjusted for medica-
ment treatment of participants, which might have an impact
on fatty acid metabolism and lead to divergent results.
Differences in associations of the FABP2 promoter hap-
lotypes with metabolic traits may result from strong but not
total linkage disequilibrium of the promoter haplotype B
with the Thr allele of the FABP2 Ala54Thr polymorphism
with an LD = 0.9 [13]. Associations with the Thr allele and
metabolic traits showed controversial results. The Thr allele
was associated with increased fasting lipid metabolism,
intra-abdominal fat, C reactive protein, IL6, lipoprotein a,
fasting insulin concentration, fasting fatty acid oxidation
and decreased insulin sensitivity, reduced glucose uptake
and obesity [23–29]. Further studies showed no influence
of the Ala54Thr polymorphism on fasting and postprandial
insulin, glucose or triglyceride levels, fat distribution and
weight loss [30–35]. Other studies found associations with
reduced subcutaneous adipose tissue, systolic blood pres-
sure and glucose levels [31, 36]. These studies were carried
out in populations with different ethnic, phenotypic and
lifestyle backgrounds. This contributes in addition to puta-
tive changes in LD between the promoter and exon poly-
morphism in these different races to diverse associations.
Further, our data revealed a reduced BMI for nonobese
but not for obese males carrying haplotype B. Hence, the
FAPB2 promoter haplotype B may bear prevention against
overweight as long as obesity has not been occurred.
At a first glance, the observed sexual dimorphism shows
inconsistencies with the phenotype of FABP2 knock out
mice [37]. Male mice lacking FABP2 have higher body
weight than wild type animals [37]. Here, a reduced BMI is
associated with the FABP2 promoter haplotype B which
showed lower basal activity than haplotype A in cell culture
experiments [13, 14, 16, 18, 38]. Assuming a functional
connection of FABP2 gene expression and BMI we tempt to
speculate that the FABP2 promoter haplotype B is in vivo
more active in males than in females. This is supported by
reports demonstrating higher activity of PPARs in male ani-
mals compared to females [39, 40] and higher responsive-
ness of FABP2 promoter haplotype B than A to PPARg/
RXRa as recently stated by us and others [41, 42]. The
physiological mechanism by which the FABP2 promoter
influences BMI remains obscure. A possible pathway is the
complex and still incomplete understood interaction
between diabetes type 2 and obesity [27, 43]. FABP2 is not
solely expressed in enterocytes but also in GLP expressing
intestinal epithelial L-cells [44]. The anti-diabetic hor-
mones GLP-1 and GLP-2 are expressed after fat ingestion
and could influence insulin sensitivity and via glucose
metabolism the triglyceride metabolism in peripheral cells.
Of course our hypothesis has to be tested by comparing the
FABP2 expression levels from human males and females.
4 Concluding remarks
We obtained evidence in a population-based sample com-
prising 8072 participants that the minor FABP2 promoter
haplotype B contribute to a reduced body weight in men.
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Table 1. Frequencies of FABP2 promoter genotypes (AA, AB, BB) and their associations with BMI as continuous variable via linear
regression
Frequencies Unit change in BMI in kg/m2 [95% confidence interval] (p-values)
All Men Women All Men Women
By genotype
All 8072 4002 4070
AA 2695 1293 1402
AB 3974 1997 1977 –0.047 [–0.26, 0.16] (0.66) –0.140 [–0.4, 0.12] (0.29) 0.048 [–0.28, 0.38] (0.78)
BB 1403 712 691 –0.206 [–0.49, 0.07] (0.15) –0.392 [–0.73, –0.05] (0.024) –0.004 [–0.44, 0.43] (0.99)
Ba) 5377 2709 2668 –0.094 [–0.23, 0.04] (0.18) –0.188 [–0.35, –0.02] (0.027) 0.007 [-0.21, 0.22] (0.95)
ByWHOBMI cat.a)
18.5–25 2729 1044 1685 –0.041 [–0.12, 0.04] (0.33) 0,011 [–0.11, 0.13] (0.86) –0.072 [–0.18, 0.04] (0.21)
25–30 3507 2105 1402 –0.067 [–0.13, 0] (0.049) –0.098 [–0.18, –0.01] (0.025) –0.021 [–0.13, 0.09] (0.71)
30–35 1355 695 660 0.037 [–0.07, 0.14] (0.51) 0.056 [–0.09, 0.2] (0.46) 0.017 [–0.14, 0.17] (0.83)
35–40 334 116 218 0.029 [–0.19, 0.24] (0.79) 0.111 [–0.28, 0.5] (0.57) –0.011 [–0.27, 0.25] (0.93)
By obesity statusa)
a30 6282 3159 3123 –0.16 [–0.39, 0.07] (0.17) –0.37 [–0.67, –0.07] (0.017) 0.01 [–0.33, 0.36] (0.94)
330 1790 843 947 –0.06 [–0.15, 0.03] (0.17) –0.10 [–0.22, 0.02] (0.10) –0.02 [–0.16, 0.12] (0.76)
Results are the b estimate (linear regression) with 95% confidence interval and p-values. All calculations were adjusted for age and
sex. The main results are in bold.
a) Additive model.
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Variants of the human intestinal fatty acid binding protein 2 gene (FABP2) are associated with traits of the
metabolic syndrome. Relevant FABP2 promoter polymorphisms c.-80_-79insT, c.-136_-132delAGTAG, c.-168_-
166delAAGinsT, c.-260GNA, c.-471GNA, and c.-778GNT result in two haplotypes A and B. Activation of
haplotypes by rosiglitazone stimulated PPARγ/RXRα leads to 2-fold higher activity of haplotype B than A. As
shown by chimeric FABP2 promoter constructs, the higher responsiveness of FABP2 haplotype B is mainly but
not solely determined by polymorphism c.-471GNA. As shown by EMSA and promoter–reporter assays, Oct-1
interacts with the −471 region of FABP2 promoters, induces the activities of both FABP2 promoter haplotypes
and abolishes the different activities of haplotypes induced by rosiglitazone activated PPARγ/RXRα. In
conclusion, ourﬁndings suggest a functional role of PPARγ/RXRα andOct-1 in the regulation of the FABP2 gene.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The human fatty acid binding protein 2 gene (FABP2, GenBank:
NM_000134.2) is located on chromosome 4q28-q31, contains four
exons and codes for a 15.1-kDa protein comprising 132 amino acid
residues [1]. It is expressed in the intestine with highest cellular
concentrations in the jejunum [2,3]. FABP2 is involved in intestinal fat
absorption [4–6]. A huge number of studies in different human
populations revealed associations between the minor allele of the
FABP2 Ala54Thr polymorphism and risk parameters of insulin
resistance [7]. Functional studies showed increased binding afﬁnity
of the variant protein to long-chain fatty acids [8]. More recently [9–
11], single nucleotide polymorphisms and insertion/deletion sites c.-
80_-79insT, c.-136_-132delAGTAG, c.-168_-166delAAGinsT and SNPs -
260GNA, c.-471GNA and c.-778GNT were identiﬁed in the 5¢ upstream
promoter region of FABP2. These polymorphisms are in complete
linkage disequilibrium resulting in only two haplotypes ANB. FABP2
promoter haplotypes were associated with postprandial triglyceride
levels [12], BMI [9] and type 2 diabetes [11]. In accordance with the
association studies, male FABP2 knock-out mice showed key symp-
toms of the metabolic syndrome [13,14]. Therefore, the expression
level of FABP2 seems to be critical for insulin sensitivity and
triglyceride metabolism. Thus, the transcriptional regulation of the
FABP2 gene is of special interest. In the present study we focus on the
regulation of FABP2 promoter haplotypes by PPARγ/RXRα and Oct-1.
2. Materials and methods
2.1. Cell culture
HeLa and CaCo2 cells were purchased from German National
Resource Centre for Biological Material (DSMZ, Braunschweig, Ger-
many). Cells were maintained in MEM (Invitrogen, Carlsbad, CA, USA),
supplemented with 10% (HeLa) or 20% (CaCo2) fetal calf serum
(Invitrogen) and 1mMnon-essential amino acids (PAA, Cölbe, Germany)
in a humidiﬁed incubator at 37 °C under an atmosphere of 5% CO2. Cells
were passaged at pre-conﬂuent densities by use of 0.05% trypsin/5 mM
EDTA (Biochrom AG, Berlin, Germany) solution every 2–3 days.
2.2. FABP2 promoter luciferase constructs
The dual luciferase systemwas used (Promega, Madison, WI, USA).
Cloning procedures were performed using Gateway Technology
(Invitrogen), described previously [11,15].
2.3. Chimera constructs
Mutations in haplotype A (pGL4.10[luc2]–FABP2(A)) and haplo-
type B (pGL4.10[luc2]–FABP2(B)) containing promoter constructs
were introduced to generate chimeras with single polymorphisms of
haplotype B in the background of haplotype A (A-xB) and vice versa
(B-xA). Single polymorphism exchange chimera constructs are
shortly named as follows: for exchange of polymorphism c.-80_-
79insT of haplotype A (rs5861422): A-80B; for c.-136_-132delAGTAG
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(rs5861423): A-136B; for c.-168_-166delAAGinsT (rs1973598): A-
168B, c.-260GNA (rs6857641): A-260B c.-471GNA (rs2282688): A-
471B; c.-778GNT (rs10034579): A-778B and vice versa. Mutation of a
putative PPARγ binding site at −623/−607 upstream of the
translation start site was introduced into the haplotype A (pGL4.10
[luc2]−FABP2(A)) and haplotype B (pGL4.10[luc2]–FABP2(B)) con-
taining promoter by exchange of a 4 base core region from CTAT to
AGCG named Amut and Bmut, respectively. Introduction of muta-
tions was performed using Quick Change in vitro mutagenesis Kit
(Stratagene, La Jolla, CA, USA). All primers were purchased from
MWG Biotech AG (Ebersberg, Germany). Sequences of primers are
available on request. Veriﬁcation of constructs was performed by
sequencing.
2.4. Expression plasmids
The cDNAs of PPARγ2 and RXRα were kindly provided by Dr. T.
Weitzel (University Medical Centre Hamburg-Eppendorf, Germany).
Cloning procedures were performed using Gateway Technology
(Invitrogen) with the pcDNA-Dest40 destination vector as described
previously [11,15,16]. The expression plasmids pcDNA3HA-Oct-1 and
its empty control vector were a gift from H. Singh (University Chicago,
IL, USA).
2.5. Transient transfections and reporter assays
Transient transfections were performed with FuGene6 (Roche,
Basel, Switzerland) according to the manufacturers instructions.
4×103 HeLa cells were plated in 96-well plates. Cells were transfected
with 30 ng (Figs. 1–2) or 25 ng (Fig. 3) pGL4.10[luc2]–FABP2-Promoter
constructs or pGL4.10[luc2] as negative control and 3 ng pGL4.74
[hRluc/TK] vector encoding Renilla luciferase as internal control. For
co-transfection with PPARγ/RXRα 33 ng (Figs. 1–2) or 25 ng (Fig. 3)
Dest40-PPARγ and RXRα expression vectors and 25 ng Dest40 empty
control vector (Fig. 3) were used. For co-transfection with Oct-1 25 ng
pcDNA3HA-Oct-1 and 75 ng empty pcDNA3HAvector were added. Co-
transfection with PPARγ/RXRα/Oct-1 was carried out with 25 ng of
each plasmid vector. The PPARγ/RXRα complex was activated 24 h
Fig. 1. Reporter activities of FABP2 promoter haplotypes and from it derived chimeras in HeLa cells were assessed 48 h after co-transfection with PPARg and/or RXRα and 24 h after
activation with rosiglitazone (Rosi) (+) or DMSO control (−) using dual luciferase assay. The Fireﬂy luciferase activities were normalized to Renilla luciferase activities and are given as
relative luciferase activities in % of FABP2 promoter haplotype A. Each experiment was performed in triplicate for each sample. The results are expressed as mean±SEM for three
independent experiments. ⁎⁎⁎pb0.001, ⁎⁎pb0.01, ⁎pb0.05, as compared with haplotype A activity in all ﬁgures. (A) Luciferase activities of FABP2 promoter haplotypes (A, B) co-
transfectedwith PPARγ, RXRα or PPARγ/RXRα are shown. (B) Alleles of each polymorphism in the FABP2 promoter haplotypes ANB are given. The positions of polymorphisms c.-80_-
79insT (rs5861422), c.-136_-132delAGAGT (rs5861423), c.-168_-166delAAGinsT (rs1973598), c.-260GNA (rs6857641), c.-471GNA (rs2282688), and c.-778GNT (rs10034579) are
named as -80, -136, -168, -260, -471, and -778, respectively.
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after co-transfection with medium containing 1% NEAA, 1% BSA and
2 μM rosiglitazone or DMSO as negative control. Luciferase activities
were measured 48 h after transfection by Dual-Luciferase® Reporter
Assay System (Promega). Relative luciferase activities of negative
control pGl4.10[luc2] were determined for each condition and were
subtracted from corresponding activities for pGL4.10[luc2]–FABP2-
Promoter constructs. Each experiment was repeated at least three
times, and each sample was studied in triplicate.
2.6. Electrophoretic mobility shift assay (EMSA)
EMSA was done as previously described [15,17]. The oligonucleotide
sequences for position −629/−602 are 5′-GCTCAGTGGCCTATCACCATT-
CAGGATC-3′ for the wild type and 5′-GCTCAGTGGCAGCGCACCATTCAG-
GATC-3′ for themutated PPARγ binding site oligo, and for position −488/
−447 are 5′-GAAAACGAATCTTATTAACTTTAGCTTTTCAACTGTATTTC-3′
for the wild type and 5′-GAAAACGAATCTTATTAACGGGCGCTTTT-
CAACTGTATTTC-3′ for themutated Oct-1 binding site oligo, respectively.
The mutated core binding sites are underlined; the base −471 is
italicized. Antibodies again PPARγ2 (sc-22020) and HNF4α (sc-6547x)
were purchased from Santa Cruz (Heidelberg, Germany) and for Oct-1
self-made by C. Brunner (University Ulm, Germany) and added to a ﬁnal
concentration of 1 μg (PPARγ) and 2 μg (Oct-1 and HNF4).
2.7. Real time RT-PCR
For RNA analysis 5.2×104 CaCo2 cells were plated in 6-well plates
and transfected with 4 μg pcDNA3HA-Oct-1 or solely Fugene 6 as
control. Total RNAwas extracted 48 h and 120 h after conﬂuent growth
with the RNeasy Kit (Qiagen, Hilden, Germany). CDNA synthesis of 1 μg
total RNA was done with Omniscript RT (Qiagen). Real time PCR was
performed with a 7300 Real-Time PCR system (Applied Biosystems,
Foster City, CA, USA) using QuantiTect SYBR Green PCR Kit (Qiagen).
Primerwere designedwith the Primer3 online tool [18] and purchased
from MWG Biotech AG. Sequences are available upon request. To
determine the relationship between cycle number (CT) and mRNA
levels the ΔΔCT method was conducted using 18S as control gene. All
procedures were carried out according to manufactures instructions.
2.8. Statistical analyses
Statistical analyses were performed with GraphPad Prism 4
(GraphPad Software, Inc., San Diego, CA) using ANOVA and unpaired
t-tests. The differences between haplotype A and B activities were
tested with two-tailed t-tests. For comparison of chimera activities
with haplotype Awe used one-tailed t-tests because we hypothesized
that activities of the chimera promoter constructs have to be above
Fig. 2. (A) Differential interaction of PPARγ with the FABP2 promoter region −623/−607 was analyzed with EMSA. Nuclear extract isolated from HeLa cells transfected with PPARγ/
RXRαwere used for each binding reaction (no extract was added in lane 1) with biotinylated wild type oligos (lanes 1–3, 5–7) or mutated PPARγ binding site oligo (lane 4). A speciﬁc
shift was diminished by 100-fold excess of unlabeled oligo (lane 3) but not by unlabeled mutated PPARγ binding site oligo (lane 5), indicated with an arrow. Super shift assays were
carried out with antibodies against PPARγ (P, lane 6) and HNF4α (H, lane 7). (B) Reporter activities of FABP2 promoter haplotypes (A, B) and from it derived chimeras with a mutated
PPARγ core binding site at position −619/−616were assessed in HeLa cells 48 h after co-transfectionwith PPARγ/RXRα and 24 h after activationwith rosiglitazone (Rosi) (+) or DMSO
control (−) using dual luciferase assay.
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promoter activities of haplotype A. All values were expressed as
means±SEM. Signiﬁcant differences were considered for p values less
than 0.05.
3. Results
3.1. The polymorphism c.-471GNA of FABP2 promoter haplotypes is
involved in determining different activities of FABP2 promoter
haplotypes induced by rosiglitazone activated PPARγ/RXRα
As published recently [19], activation of FABP2 promoter haplo-
types by rosiglitazone stimulated PPARγ/RXRα leads to higher activity
of haplotype B than A. As shown in Fig.1A, the rosiglitazone stimulated
PPARγ/RXRα induced absolute activity (AA) of haplotype B is 2.0-fold
higher than haplotype A. The induction ratio (IR) between un-
stimulated and rosiglitazone stimulated PPARγ/RXRα induced activity
is 3.3 for haplotype A and 4.9 for haplotype B. To identify the causal
polymorphism(s) for this haplotype difference, we sequentially
introduced alleles of FABP2 haplotype B into A (A-xB) and compared
the rosiglitazone stimulated PPARγ/RXRα induced activities of result-
ing FABP2 promoter chimeras with those of haplotype A and B. As
shown in Fig. 1B, AA of FABP2 promoter chimeras A-80B (1.1-fold
compared to A), A-136B (-1.1-fold), A-168B (-1.1.-fold), and A-778B
(1.1-fold) is similar to haplotype A (1.0-fold). AA of chimera A-471B
(1.4-fold) is between haplotype B (2-fold) and A (1.0-fold). The
opposite chimeras B-471A (1.1-fold) showed similar AA thanhaplotype
A. Comparison of IRs revealed that chimera A-471B (4.9-fold) exhibits
similar IR than haplotype B (4.7-fold). The IR of the opposite chimeras
B-471A (4.0-fold) is more similar to haplotype B (4.7-fold) than A (2.7-
fold). Thus, we reasoned that the polymorphism c.-471GNA of FABP2
promoter haplotypes is involved in determining rosiglitazone stimu-
lated PPARγ/RXRα induced activities of haplotype A and B.
3.2. Identiﬁcation of a PPARγ binding site at position −623/−607 of the
FABP2 promoter
A TRANSFAC Professional database search revealed a putative
PPARγ binding site at position −623/−607 of the FABP2 promoter. This
Fig. 3. (A) Differential interaction of Oct-1 with FABP2 promoter region containing the allele A of polymorphisms c.-471GNA (rs2282688) was analyzed with EMSA. Nuclear extract
isolated from HeLa cells was used for each binding reaction (no extract was added in lane 1) with biotinylated haplotype A oligonucleotides (lanes 1–4, 6–8) or biotinylated mutated
Oct-1 binding site oligonucleotide (lane 5). A speciﬁc shift was diminished by 100-fold excess of unlabeled haplotype A oligo (lane 3) but not by unlabeled mutated Oct-1 binding site
oligo (lane 4), indicatedwith an arrow. Super shift assaywas carried outwith an antibody against Oct-1 (O, lane 6) and control antibodies again PPARγ (P, lane 7 andHNF4α (H, lane 8).
(B) Gene expression of Oct-1 and FABP2 in Caco2 cells was assessed 72 h after co-transfection and 48 h or 120 h after post-conﬂuencewith Oct-1 using SYBR green RT-PCR. Results are
measuredwith theΔΔCTmethod and 18S as control gene and are expressed as fold-change against Fugene 6 transfection. Each experimentwas performed in triplicate for each sample.
The results are expressed as mean±SEM for two independent experiments. (C). Reporter activities of FABP2 promoter haplotypes (A, B) in HeLa cells were assessed 48 h after co-
transfection with empty control vector Dest40 or Oct-1 using dual luciferase assay. The Fireﬂy luciferase activities were normalized to Renilla luciferase activities and are given as
relative luciferase activities in % of Dest40 transfected FABP2 promoter haplotype A. (D) Reporter activities of FABP2 promoter haplotypes (A, B) in HeLa cells were assessed 48 h after
co-transfectionwith empty control vector Dest40, PPARγ/RXRα, or PPARγ/RXRα/Oct-1 and 24 h after activationwith rosiglitazone (Rosi) (+) or DMSO control (−) using dual luciferase
assay.
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site was tested for PPARγ binding using EMSA. As shown in Fig. 2A,
with a −629/−602 probe we obtained a shift (arrow, lane 2) when
using nuclear extract from HeLa cells transfected with PPARγ/RXRα.
100-fold molar excess of the unlabeled probe (lane 3) but not a
mutated probe (lane 5) abolished the shift. A labeled probe with a
mutated PPARγ core binding site did not display a shift (lane 4). A
super shift assay with an antibody against PPARγ (lane 6) but not
HNF4α (lane 7) abrogated the shift. To explore the functional
importance of the −623/−607 region for FABP2 promoter haplotype
difference, promoter–reporter analysis with haplotype mutants was
done. As shown in Fig. 2B, incorporation of a 4 bp mutation into the
core sequence of PPARγ-consensus at position −619/−616 leads to a
reduction of the AA of FABP2 promoter haplotypes by a factor of
−1.2 (haplotype A) and −1.6 (B), respectively. Mutation of the
putative PPARγ binding site shows a small decrease or increase in IR
for haplotype A (from 3.7-fold to 4.7-fold) and B (6.6-fold to 6.0-
fold). Taken together, the identiﬁed PPARγ binding site at positions
−623/−607 of the FABP2 promoter is functional but its inﬂuence on
the rosiglitazone stimulated PPARγ/RXRα induced activity of FABP2
promoter haplotypes is limited.
3.3. Oct-1 binds to a FABP2 promoter region containing the c.471GNA
polymorphism and abolishes the different activities of FABP2 promoter
haplotypes induced by rosiglitazone activated PPARγ/RXRα
A putative Oct-1 binding site in the FABP2 promoter region
containing the c.471GNA polymorphism was found by TRANSFAC
Professional database search. To see if the −471 region shows
binding of the ubiquitous expressed Oct-1 [20], electro mobility
shift and super shift assays were performed with nuclear protein
extracts from HeLa cells. As shown in Fig. 3A, with a FABP2
promoter probe containing the −471 region we observed a speciﬁc
signal (lane 2, arrow), which could be displaced with the
unlabeled probe (lane 3). This total displacement was not observed
by a competitor with a mutation in the Oct-1 core binding site at
positions −470/−467 (lane 4). Only unspeciﬁc binding was
generated by a labeled probe with the mutated Oct-1 binding
site (lane 5). A super shift assay with an antibody against Oct-1
(lane 6), but not PPARγ (lane 7) and HNF4α (lane 8), abolished the
speciﬁc shift completely. Differences in binding afﬁnity to −471G
and −471A probes could not be detected by a gradually increasing
excess of unlabeled probes (data not shown). Next, we determined
the inﬂuence of Oct-1 on FABP2 mRNA expression in intestinal
CaCo2 cells. As shown in Fig. 3B, a 2–3.5-fold over-expression of
Oct-1 has no inﬂuence on mRNA steady level of FABP2. In order to
reveal the effect of Oct-1 on the transcriptional activity of FABP2
promoter haplotypes we performed promoter–reporter analysis. As
shown in Fig. 3C, Oct-1 causes similar activation of FABP2
promoter haplotype A and B. In the presence of PPARγ/RXRα,
Oct-1 induces the basal activity of FABP2 promoter haplotype A
and B to the same level (Fig 3D). These basal activities could not
be induced by rosiglitazone. AA of haplotype A was signiﬁcantly
enhanced (1.6-fold) by Oct-1, whereas AA of haplotype B was not
altered (fold-change −1.1). Thus, Oct-1 abolishes the different
activities in FABP2 promoter haplotypes induced by rosiglitazone
activated PPARγ/RXRα.
4. Discussion
The FABP2 promoter haplotypes are associated with traits of the
metabolic syndrome in candidate gene approaches [9,11,12].
Though, in genome-wide association studies the FABP2 locus was
linked with physical ﬁtness in DZ female twins [21] but not with
type 2 diabetes and related traits [22–24]. As shown previously by
us [11] and others [9,10], the basal transcription of the rare FABP2
promoter haplotype B is about 2–3-fold lower than the common
haplotype A in FABP2 expressing post-conﬂuent Caco2 cells.
Recently, we showed that this different activity is due to decreased
binding afﬁnity of GATA factors to the c.-80_-79insT polymorphism
[17]. Interestingly, in FABP2 non-expressing HeLa cells activation of
FABP2 promoters by PPARγ/RXRα lead to higher activity of
haplotype B in comparison to A [19]. In the present study, this
higher responsiveness of FABP2 promoter haplotype B was
investigated in more detail. At ﬁrst glance, the rosiglitazone
dependent PPARγ/RXRα induced different activities of FABP2
promoter haplotypes seem not to be important in vivo since
FABP2 is expressed in the small intestine [2] were PPARα and
PPARδ are predominantly expressed [25]. Whereas, the higher
activating potential of FABP2 promoter haplotype B might result in
an ectopic expression of FABP2 in PPARγ expressing tissues of
haplotype B carriers. This might explain the FABP2 promoter
association with diabetes type 2 [11], since PPARγ is expressed in
pancreatic beta cells [26]. Further, PPARγ was associated in
genome-wide association studies with type 2 diabetes and obesity
[22–24], which might contribute to FABP2 associations. Thus,
pancreatic beta cells and adipocytes from FABP2 promoter
haplotype B carriers should be used to test this hypothesis.
By means of reporter assays, we measured the rosiglitazone
stimulated PPARγ/RXRα induced absolute activities (AA) as well as
the induction ratio (IR) between un-stimulated and rosiglitazone
stimulated PPARγ/RXRα induced activities of FABP2 haplotype A, B
and haplotype chimeras. We found that polymorphism c.-471GNA is
involved in determining different AA and IR of FABP2 promoter
haplotypes. We have to admit, that the AA of chimera A-471B and
the IR of B-471A are not in complete accordance to the
corresponding haplotypes B and A, respectively. Therefore, other
polymorphism than c.-471GNA or a combination of polymorphisms
could be involved in determining different responsiveness of FABP2
promoter haplotypes. Surprisingly, a functional PPARγ binding site
was not found in the −471 region but at position −623/−607 of the
FABP2 promoter. Based on EMSA, we identiﬁed a PPARγ binding
site at position −623/−607 of the FABP2 promoter. Activation of
−623/−607 promoter mutants by PPARγ/RXRα revealed that this
site has limited or no inﬂuence on the activity of haplotype A or B,
respectively. Thus, the functionality and importance of the −623/
−607 PPARγ binding site is questionable. Further PPARγ binding
sites seem to be relevant for the induction of FABP2 promoter
haplotype activity by PPARγ.
So far, Oct-1 has been described as an important transcription
factor for genes involved in immune system regulation [27]. The
expression of housekeeping genes encoding histone H2B or snRNA
is also dependent on Oct-1 [28]. In the present study we identiﬁed
FABP2 as a potential target gene of Oct-1. The activity of FABP2
promoter haplotypes is induced by Oct-1 by factor of three.
Furthermore, the region of the FABP2 promoter containing the c.-
471GNA polymorphism interacts with Oct-1. Interestingly, Oct-1
abolishes the different activities in FABP2 promoter haplotypes
induced by rosiglitazone activated PPARγ/RXRα. Thus, high con-
centration of Oct-1 can override the effect of PPARγ/RXRα on
different activities of FABP2 promoter haplotypes. In contrast to the
promoter–reporter assays in HeLa cells, we found no effect of Oct-1
on FABP2 mRNA steady level in CaCo2 cells. Thus, our ﬁndings
seem to be not relevant for intestinal FABP2 expression but could
be important for an ectopic expression of FABP2 in PPARγ/RXRα
and Oct-1 expressing tissues. Of course, ex vivo or in vivo
approaches are necessary to test this hypothesis. Based on our
ﬁndings, a functional interaction of PPARγ/RXRα and Oct-1 can be
also considered. Supportively, a link between fat metabolism and
Oct-1 was revealed by direct interaction between RXR and Oct-1
[29]. More indirectly, PPARγ induces the expression of the Oct-1
[30]. In conclusion, our ﬁndings suggest a functional role of PPARγ/
RXRα and Oct-1 in the regulation of the FABP2 gene.
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a b s t r a c t
The microsomal triglyceride transfer protein (MTTP) is a key regulator in the assembly and secretion of
chylomicrons and very low density lipoprotein (VLDL) in the intestine and in liver. Associations between
MTTP variants and traits of the metabolic syndrome are carried out in relatively small cohorts and are not
consistent.
We analysed MTTP polymorphisms in 7582 participants of the KORA study cohort. Seven htSNPs cov-
ering a 52 kb region of the MTTP locus and two cSNPs (I128T, H297Q) were selected.
A MTTP haplotype containing the minor allele of H297Q showed a significant decrease of 0.636 (95%
CI: 1.226, 0.046; p = 0.035) BMI units in females but not in males. In comparison to homozygous H-
carriers for the major allele of the MTTP H297Q polymorphism, homozygous Q297Q carriers showed a
significant decrease in BMI of 0.425 BMI units (95% CI: 0.74, 0.12; p = 0.007), in waist circumference
of 0.990 cm (95% CI: 1.74, 0.24; p = 0.01) and in total cholesterol of 0.039 mmol/l (95% CI: 0.07, 0;
p = 0.03). Heterozygous Q-carriers displayed a reduction in BMI of0.183 BMI unit (95% CI: 0.33, 0.04;
p = 0.012), in waist circumference of 0.45 cm (95% CI: 0.8, 0.1; p = 0.01) and in total cholesterol of
0.103 mmol/l (95% CI: 0.18, 0.03; p = 0.01). Gender stratified statistics revealed a significant reduc-
tion of 0.657 BMI units (95% CI: 1.14, 0.18; p = 0.007), 1.437 cm waist circumference (95% CI:
2.55, 0.32; p = 0.01) and 0.052 mmol/l total cholesterol (95% CI: 0.1, 0.01; p = 0.03) for females
homozygous for the Q297Q polymorphism. Females carrying the Q-allele showed a decrease of
0.259 BMI unit (95% CI: 0.48, 0.04; p = 0.023), 0.662 cm waist circumference (95% CI: 1.18,
0.14; p = 0.01) and 0.111 mmol/l total cholesterol (95% CI: 0.21, 0.01; p = 0.03).
Our association analysis in a large population based study cohort provides evidence that the minor
allele of the MTTP H297Q polymorphism is associated with lower BMI, waist circumference and total
cholesterol in females but not in males.
 2008 Elsevier Inc. All rights reserved.
Introduction
The microsomal triglyceride transfer protein (MTTP, OMIM
accession number: 157147; GenBank: NM_000253.2) gene is
located on chromosome 4q24, contains nineteen exons and codes
for a 97.4 kDa protein comprising 876 amino acid residues. MTTP
is expressed in the liver, the small intestine and the heart. It plays
a critical role in the assembly and secretion of very low density lipo-
proteins (VLDLs) and chylomicrons [1,2]. In theMTTP gene common
regulatory (493G > T,400A > T,164T > C) and nonsynonymous
(I128T, H297Q) polymorphismswere described [3]. Polymorphisms
493G > T (rs1800591), 400A > T (rs1800803), 164T > C
(rs1800804) and I128T (rs3816873) are in complete linkage
disequilibrium in Caucasian [3,4]. Several studies indicated that
theminor alleles of these polymorphisms are associated with lower
LDL levels and protect against risk parameters of the metabolic
syndrome [3,5–14]. Opposite or no associationswere found in other
studies [15–22]. Since these initial association studies were carried
out in relatively small cohorts,we analysedMTTPvariants regarding
their associations to traits of themetabolic syndrome in7582partic-
ipants of the KORA study cohort (S3, S4).
Material and methods
Study population
In the Southern German region of Augsburg including the city of
Augsburg and the two surrounding counties, population-based
1096-7192/$ - see front matter  2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ymgme.2008.09.004
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surveys of the 25–74 year old population in groups of age range of
5 years were implemented in 1984 as part of the WHO MONICA
(multinational MONItoring of trends and determinants in Cardio-
vascular disease) project and continued since 1996 within the
KORA (Kooperative Gesundheitsforschung in der Region Augsburg)
platform. The aims of the surveys were to describe the prevalence
of common diseases and their risk factors in a representative
sample of the adult general population. The current study included
the survey of the years 1994–1995 (MONICA S3) including 4856
participants and the survey of the years 1999–2001 (KORA S4)
including 4261 participants yielding 9117 recruited participants.
The study population of S3 and S4 consisted of all German resi-
dents of the Augsburg region who were born between 1920 and
1975 identified through the public record office. More than 99.5%
of the participants were Caucasian. The high standards of the
WHO MONICA project applied to both surveys. All study partici-
pants underwent a standardized interview, a physical examination,
and blood withdrawal by trained staff and signed a consent form of
the Bavarian Ethics committee and the Ethics committee of the
University of Munich. For determination of body weight and
height, participants were asked to remove shoes and heavy cloth-
ing. The weight measurements were done with a calibrated body
weight scale (SECA 709) and were carried out with an accuracy
of 0.1 kg. The body height was read to the nearest 0.5 cm on a body
height scale. BMI (kg/m2) was calculated as weight in kilograms
divided by height in square meters. The pooled data analysis
included only 7582 individuals out of 9117, because complete
information on age, sex, BMI and 9 genotypes were not available
for the whole group. There was no overlap between the two
surveys by design.
Genotyping
Genotyping was performed using a MALDI TOF MS system
(Sequenom, Mass EXTEND, San Diego, USA). Haplotype tagging
SNPs (htSNPs) with a minor allele frequency >0.1 were selected
in order to cover the whole MTTP gene locus (52 kb). The selection
was based on Haploview 3.2 [23]. Coding SNPs (cSNPs) rs3816873
(I128T) and rs2306985 (H297Q) were selected based on previous
studies and suggested functionality [3,4,13]. Sequences of primers
and assay probes are available on request.
Statistical methods
We used a linear regression model with BMI as continuous
outcome for both studies combined; the unit change in BMI by
the DNA variants was estimated. Haplotype analysis was carried
out with the statistical software R (V. 2.3.1. including haplo.stats
package) using the haplo.glm procedure. This procedure performs
an iterative two-step Estimation-Maximization (EM)-algorithm,
with the posterior probabilities of pairs of haplotypes per subject
used as weights to update the regression coefficients, and the
regression coefficients used to update the posterior probabilities.
Haplotypes were included into the regression model all at once ex-
cept the most common haplotype. Using the expected number of
copies of haplotype implies an additive model for each haplotype.
Results
In order to analyse the association between MTTP variants and
anthropometric risk parameters, seven htSNPs (rs1503777,
rs3811800, rs105763, rs2035816, rs982424, rs2903202,
rs1491244) and two nonsynonymous cSNPs (rs3816873,
rs2306985) were genotyped in 9117 participants of the KORA
study cohort (S3, S4). htSNPs with a minor allele frequency >0.1
were selected in order to cover the whole MTTP gene locus
(52 kb). Coding SNPs (cSNPs) rs3816873 (I128T) and rs2306985
(H297Q) were selected based on previous studies and suggested
functionality [3,4,13]. Details of the study cohort were published
recently [24,25]. In short, the participants were 25–74 years of
age, the range of BMI was 14–57 kg/m2 and approximately 50%
were female. The selected htSNPs comprise a 52 kb region of the
MTTP locus. The selected cSNPs lead to an amino acid exchange
from I128 to T128 (rs3816871) and H297 to Q297 (rs2306985),
respectively. The two other known cSNPs Q95H and Q244E of the
MTTP gene were not genotyped because of their low frequencies.
Haplotypes were computed with the nine htSNPs and cSNPs. As
shown in Table 1, we identified nine haplotypes with frequencies
between 2.7 and 53.0%. The minor allele frequencies of I128T and
H297Q were 27.2 and 35.96%, respectively. Next, we analyzed
associations between MTTP haplotypes (Table 1) or single SNPs
(Table 2) with BMI, waist circumference and total cholesterol by
linear regression analysis. Gender-stratified statistics were also
done.
As shown in Table 1, haplotype VII showed a significant
decrease of 0.636 (95% CI: 1.226, 0.046; p = 0.035) BMI units
in females but not in males in comparison to the major haplotype
I. Other haplotypes were not significantly associated with BMI.
With the exception of H297Q, we found no appreciable association
of BMI, waist circumference and cholesterol levels with single
MTTP SNPs. Compared with homozygous H-carriers (H297H) for
the major allele of the MTTP H297Q polymorphism, homozygous
Q297Q carriers showed a significant decrease in BMI of 0.425
BMI units (95% CI: 0.74, 0.12; p = 0.007) and in waist circumfer-
ence of 0.990 cm (95% CI: 1.74, 0.24; p = 0.01) in the whole
study group (Table 2). Carriers of the minor allele of MTTP
H297Q SNP showed a significant reduction in BMI of 0.183 BMI
unit (95% CI: 0.33, 0.04; p = 0.012) and waist circumference of
Table 1
Associations of MTTP haplotypes with BMI as continuous variable
Haplotypes Frequencies Unit change in BMI in kg/m2 [95% confidence interval] (p values)
All (%) Men (%) Women (%) Alla Menb Womenb
I, 212212112 53.0 53.7 52.3
II, 212112212 13.5 13.3 13.7 I vs II 0.143 [0.362, 0.077] (0.204) 0.023 [0.248, 0.293] (0.87) 0.305 [0.624, 0.014] (0.061)
III, 121112112 11.0 10.9 11.1 I vs III 0.144 [0.092, 0.379] (0.232) 0.050 [0.237, 0.337] (0.733) 0.265 [0.084, 0.614] (0.136)
IV, 221122221 5.9 5.8 5.9 I vs IV 0.090 [0.402, 0.221] (0.569) 0.044 [0.429, 0.342] (0.825) 0.168 [0.627, 0.291] (0.472)
V, 121112221 3.8 3.7 3.9 I vs V 0.275 [0.65, 0.1] (0.151) 0.172 [0.642, 0.298] (0.473) 0.299 [0.840, 0.242] (0.278)
VI, 221122222 3.2 3.2 3.1 I vs VI 0.009 [0.403, 0.420] (0.967) 0.134 [0.631, 0.363] (0.596) 0.156 [0.426, 0.738] (0.598)
VII, 222111212 3.1 2.9 3.3 I vs VII 0.379 [0.794, 0.036] (0.073) 0.077 [0.595, 0.442] (0.771) 0.636 [1.226, 0.046] (0.035)
VIII, 222112212 2.8 2.7 2.9 I vs VIII 0.106 [0.54, 0.328] (0.631) 0.096 [0.629, 0.438] (0.725) 0.114 [0.709, 0.481] (0.708)
IX, 122111212 2.7 2.7 2.7 I vs IX 0.33 [0.772, 0.113] (0.144) 0.462 [1.002, 0.078] (0.094) 0.221 [0.804, 0.362] (0.458)
Results are the beta estimate (linear regression) with 95% confidence interval and p values. Haplotype designation: the allele with the higher prevalence is denoted with a, the
minor allele with b. The order of polymorphisms corresponds to their position in the 50 to 30 direction of the gene: rs1503777, rs3811800, rs3816873 (I128T), rs105763,
rs2035816, rs982424, rs2306985 (H297Q), rs2903202, rs1491244. The main results are in bold.
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0.45 cm (95% CI: 0.8, 0.1; p = 0.01). Gender stratified statistics
revealed a significant reduction of 0.657 BMI units (95% CI:
1.14, 0.18; p = 0.007) and waist circumference of 1.437 cm
(95% CI: 2.55, 0.32; p = 0.01) for females homozygous for the
Q297Q polymorphism. Females carrying the Q-allele showed a
decrease of 0.259 BMI unit (95% CI: 0.48, 0.04; p = 0.023)
and waist circumference of 0.662 cm (95% CI: 1.18, 0.14;
p = 0.01). These associations were not observed in males.
Association of total cholesterol with the Q-allele showed a
reduction of 0.0391 mmol/l (95% CI: 0.07, 0; p = 0.03) (Table
2). Homozygous carriers displayed a total cholesterol reduction
of 0.103 mmol/l (95% CI: 0.18, 0.03; p = 0.01). After stratifica-
tion for gender, female but not male Q-allele carrier had a
0.052 mmol/l (95% CI: 0.1, 0.01; p = 0.03) lower total choles-
terol. Female homozygous carriers exhibited a total cholesterol
reduction of 0.111 mmol/l (95% CI: 0.21, 0.01; p = 0.03). No
association between the H297Q polymorphism and HDL- or LDL-
cholesterol was observed (data not shown).
Discussion
MTTP is a key regulator of chylomicron and VLDL assembly and
secretion in the intestine and in liver. Loss of function mutations in
the MTTP gene lead to a truncated protein and cause abetalipopro-
teinemia [26], fat malabsorption [27], hypercholesterolemia [6]
and hepatic steatosis [28]. Functional studies of MTTP promoter
haplotypes comprising SNPs 493G > T (rs1800591), 400A > T
(rs1800803) and 164T > C (rs1800804) revealed two fold lower
activity of the major haplotype 493G/400A/164T in compari-
son to the minor haplotype 493T/400T/164C [4]. Further, the
major allele of MTTP I128T confers increased functionality of the
protein [29]. The functional promoter and I128T polymorphisms
are in complete linkage disequilibrium: Therefore, the resulting
two functional MTTP haplotypes A and B contain combinations of
a high (low) promoter activity and low (high) protein functionality.
The overall consequences of this opposite effects are not known.
However, studies of polymorphism 493G > T which covered the
two functional haplotypes showed positive, negative, or no associ-
ations with traits of the metabolic syndrome [3,5–14].
Here we analyzed seven htSNPs as well as two common cSNP in
the MTTP gene for associations with BMI, waits circumference, and
total cholesterol in a large population based study cohort compris-
ing 7582 participants [24,25]. The selected SNPs cover a 52 kb
MTTP gene region and contain the functional haplotypes as well
as cSNP H297Q. We found no association between BMI, waist
circumference, or total cholesterol and I128T which represent the
functional haplotypes A and B. Our finding supports the idea that
the overall effects of these haplotypes are neutral. To our surprise,
the largely unnoted cSNP H297Q [3] showed association with BMI,
waist circumference and total cholesterol, whereupon the minor
Q-allele carrier showed a general reducing effect. Thus, it seems
to be fruitful to reanalyse published results as shown for the asso-
ciation between MTTP H297Q SNP and traits of the metabolic
syndrome. An exchange of His to Gln at position 297 results in a
change of a weakly basic to a neutral side chain making this side
more hydrophobic. Amino acid residue 297 is located in a domain
relevant for lipid binding, suggesting functionality of H297Q SNP.
Of course, functional studies are necessary to test this hypothesis.
A direct link between MTTP functionality and BMI or waist cir-
cumference is not apparent. However an interaction with total
cholesterol is plausible, since MTTP is relevant for chylomicron
and VLDL maturation via apoB binding. Accordingly, involvement
of the MTTP gene in the development of fat malabsorption, hepatic
steatosis and insulin resistance were demonstrated in patients
with loss of function mutations in the MTTP gene [3,27] as well
as in MTTP knock-out mice [28,30]. Associations with the MTTP
H297Q polymorphism were only found in females. A sex-specific
response of the MTTP 493G > T to dietary lipid changes was
described recently [31]. MTTP and apoB are building a complex,
therefore protein interactions have to be considered. It was shown
that apoB mRNA and protein levels are higher in females [32,33].
Accordingly, altered MTTP activity by H297Q polymorphism may
have more pronounced effects in females than in males resulting
in a stronger phenotype change.
In conclusion, our association analysis in a large population
based study cohort provides evidence that the minor allele of the
MTTP H297Q polymorphism is associated with lower BMI, waist
circumference and total cholesterol in females but not in males.
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Abstract 
 
Context: The H-allele of the R298H polymorphism in the Prostaglandin E Synthase 2 (PTGES2) gene 
was associated with lower risk of diabetes type 2. 
Aim: In order to explore the association between the PTGES2 R298H SNP and BMI, we analysed the 
R298H SNP (rs13283456) and three htSNPs (rs884115, rs10987883, rs4837240) covering a 20 kb 
gene region in population based surveys of the KORA study cohort with 8079 participants. 
Results: A statistically significant difference in BMI between the heterozygous PTGES2 R298H 
genotype and the homozygous R/R genotype was found in males but not in females. Males with the 
R/H genotype showed a decrease in BMI of -0.30 BMI units (95% CI: -0.55, -0.04, p=0.02) in 
comparison to R/R males. A haplotype comprising the minor allele of PTGES2 R298H showed a 
significant decrease of -0.23 BMI units in males (-0.45, -0.02; p=0.04) but not in females. Other 
haplotypes and single htSNPs were not significantly associated with BMI. 
Conclusion: We found a marginal but significant influence of the PTGES2 298H SNP on BMI in a 
large population based study. 
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Introduction 
Prostaglandin E2 (PGE2) is produced in diverse tissues and is involved in a number of biological 
processes including inhibition of lipolysis, induction of hypertrophy of adipose tissue and leptin 
secretion (Gaskins et al. 1989; Fain et al. 2001; Serhan and Levy 2003; Murakami and Kudo 2004). 
PGE2 is synthesized by PGE2 synthases (PTGES) in concert with phospholipase A2 and 
cyclooxygenases. Three PTGES isoforms are known. The microsomal PTGES (PTGES1) is mainly 
involved in inflammation, whereas the role of the cytosolic PTGES is uncertain (Gaskins et al. 1989; 
Murakami and Kudo 2004). The membrane-associated PTGES2 is mainly expressed in tissues such as 
adipocytes with low PTGES1 levels and is not inducible by inflammation (Tanikawa et al. 2002). The 
PTGES2 (NM_025072) gene maps to the chromosomal band 9q34.11, which was significantly 
associated with body weight (Wilson et al. 1991). Recently, we showed in three independent study 
populations that the PTGES2 R298H (rs13283456) polymorphism is associated with type 2 diabetes 
and related traits (Fisher et al. 2007; Lindner et al. 2007; Nitz et al. 2007). Whether the rare H-allele 
contributes to body mass index (BMI) remained questionable. Therefore, we analyzed the PTGES2 
R298H SNP with BMI in large (n=8079) populations based surveys (S3, S4) of the KORA study 
cohort. 
 
 
Material and Methods 
Study population 
In the Southern German region of Augsburg including the city of Augsburg and the two surrounding 
counties, population-based surveys of the 25-74 year old population in groups of age range of 5 years 
were implemented in 1984 as part of the WHO MONICA (multinational MONItoring of trends and 
determinants in Cardiovascular disease) project and continued since 1996 within the KORA 
(Kooperative Gesundheitsforschung in der Region Augsburg) platform. The aims of the surveys were 
to describe the prevalence of common diseases and their risk factors in a representative sample of the 
adult general population. The current study included the survey of the years 1994-1995 (MONICA 
S3) including 4856 participants and the survey of the years 1999-2001 (KORA S4) including 4261 
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participants yielding 9117 recruited participants. The study population of S3 and S4 consisted of all 
German residents of the Augsburg region who were born between 1920 and 1975 identified through 
the public record office. More than 99.5% of the participants were Caucasian. The high standards of 
the WHO MONICA project applied to both surveys. All study participants underwent a standardized 
interview, a physical examination, and blood withdrawal by trained staff and signed a consent form of 
the Bavarian Ethics committee and the Ethics committee of the University of Munich. For 
determination of body weight and height, participants were asked to remove shoes and heavy 
clothing. The weight measurements were done with a calibrated body weight scale (SECA 709) and 
were carried out with an accuracy of 0.1 kg. The body height was read to the nearest 0.5 cm on a body 
height scale. BMI (kg/m²) was calculated as weight in kilograms divided by height in square meters. 
The pooled data analysis included 8079 individuals with complete information on age, sex, BMI and 
genotypes. There was no overlap between the two surveys by design. 
 
Genotyping 
Genotyping was performed using a MALDI TOF MS system (Sequenom, Mass EXTEND, San 
Diego, USA). Sequence information of the PTGES2 gene (ID: 80142) was derived from Genbank 
(www.ncbi.nlm.nih.gov). As described (Nitz et al. 2007), the R298H SNP (rs13283456) was 
identified by re-sequencing and htSNPs were selected by analysing a 20 kb region comprising 
PTGES2 (Chrom 9: pos. 127.952.200-127.972.200) using Haploview 3.2. HtSNPs with a minor allele 
frequency >0.1 (rs10987883, rs4837240, rs884115) were obtained from CEPH HapMap data release 
21 (www.hapmap.org). Sequences of primers and assay probes are available on request. 
 
Statistical methods 
We used a linear regression model with BMI as continuous outcome for both studies combined; the 
unit change in BMI by the DNA variants was estimated. Haplotype analysis was carried out with the 
statistical software R (V. 2.3.1. including haplo.stats package) using the haplo.glm procedure. This 
procedure performs an iterative two-step Estimation-Maximization (EM)-algorithm, with the posterior 
probabilities of pairs of haplotypes per subject used as weights to update the regression coefficients, 
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and the regression coefficients used to update the posterior probabilities. Haplotypes were included 
into the regression model all at once except the most common haplotype. Using the expected number 
of copies of haplotype implies an additive model for each haplotype.  
 
 
Results 
A total of 8079 subjects of the KORA study cohort (S3, S4) were genotyped for the PTGES2 R298H 
SNP. Three htSNPs (rs884115, rs10987883, rs4837240) covering a 20 kb region of the PTGES2 gene 
were also genotyped. The participants were 25-74 years of age, approximately half were male and the 
range of BMI was 14-57 kg/m2. More details of the study cohort were described elsewhere (Heid et al. 
2005). Gender-stratified statistics of the BMI and their associations to the PTGES2 R298H SNP as 
well as haplotypes are provided in table 1. For the three htSNPs, we found no significant associations 
to BMI (not shown). In females, no significant association between PTGES2 genotypes and BMI was 
observed. We found a statistically significant difference in BMI between heterozygous PTGES2 
R298H males and males homozygous for the major allele (R/R). R/H males showed a decrease in 
BMI of -0.30 BMI units (95% CI: -0.55, -0.04, p= 0.02) in comparison to R/R males. This result was 
congruent with the association between BMI and haplotype II, which covered the minor allele of 
R298H. This haplotype showed a significant decrease of -0.19 BMI units (-0.37, -0.01; p=0.04) for 
the hole study population and -0.23 BMI units (-0.45, -0.02; p=0.04) in males. There was no 
association with haplotypes detected in females. Other haplotypes were not significantly associated 
with BMI. Further, no linkage of the R298H polymorphism with obesity status (BMI>30) or waist to 
hip ratio was observed (not shown). 
 
 
Discussion 
The metabolite of PTGES2 PGE2 possesses anti-lipolytic activity, induces hypertrophy in adipose 
tissue and is involved in secretion of leptin (Richelsen 1987; Gaskins et al. 1989; Richelsen 1991; 
Richelsen et al. 1991; Fain et al. 2000; Fain et al. 2001; Serhan and Levy 2003; Murakami and Kudo 
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2004). These characteristics, the linkage of the 9q34.11 PTGES2 gene region with body weight 
(Wilson et al. 1991) and the association between PTGES2 R298H SNP and traits of the metabolic 
syndrome (Fisher et al. 2007; Lindner et al. 2007; Nitz et al. 2007) raise the PTGES2 gene as a 
candidate gene for obesity. On the other hand, genome-wide association studies did not ennoble 
PTGES2 as a prime candidate for obesity (Herbert et al. 2006; Frayling et al. 2007; Scuteri et al. 
2007; Liu et al. 2008). In order to unravel the influence of genetic variance of PTGES2 on body 
weight, we used a large population based study cohort comprising 8079 participants. Based on this 
large association study, a reduced BMI of -0.30 BMI units was observed in males heterozygous for 
the PTGES2 R298H SNP. A haplotype comprising the minor allele of R298H was also associated 
with a reduced BMI. Thus, the PTGES2 298H allele leads to a slight reduction of the BMI in males. A 
protective effect of the H-allele was also described for diabetes type 2, impaired glucose tolerance, 
fasting and postprandial insulin levels and HOMA indices for ß-cell function and insulin resistance 
(Herbert et al. 2006; Frayling et al. 2007; Scuteri et al. 2007; Liu et al. 2008). The BMI lowering 
effect of the His-allele was solely observed in heterozygous but not in homozygous males. Although 
this specific association remain ambiguous, based on functional considerations suggestive hypotheses 
can be formulated. We assumed that the heterozygous genotype leads to a slight reduction in overall 
PTGES2 function causing a reduced PGE2 level. This could result in a lower BMI, because PGE2 
possesses anti-lipolytic activity and induces adipocyte hypertrophy (Richelsen 1987; Richelsen 1991; 
Richelsen et al. 1991). An even stronger reduction of PGE2 levels in homozygous carriers of the 
PTGES2 298H allele may induces compensatory up-regulation of other PTGES2 enzymes. The 
reason for a specific protection of the PTGES2 298H allele in males might be caused by gender-
specific PGE2 levels which might be regulation by transcriptional repression of PTGES genes via 
PPARγ (Mendez and LaPointe 2003) since PPARγ is regulated in a sex specific manner (Ciana et al. 
2007). However, this polymorphism has only a small impact on overall BMI status, although, the H-
allele may contribute to a risk-reduction of diabetes type 2 and related traits.  
In future functional studies it would be interesting to analyse the gender specific connections between 
lipolysis, BMI and the PTGES2 R298H. In conclusion, our results in a large population based study 
cohort provide evidence that the PTGES2 298H allele is associated with lower BMI.  
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Table 1. Frequencies of PTGES2 R298H genotypes (R/R, R/H, H/H) and haplotypes and their associations with BMI as continuous variable via linear regression 
 
 Frequencies  Unit change in BMI in kg/m2 [95 % confidence interval] (p values) 
 All Men Women   All Men Women 
Genotypes n n n  Comparison    
all  8079 4013 4066      
R/R 5203 2620 2583      
R/H 2549 1228 1321  R/R vs R/H -0.17 [-0.37, 0.04] (0.11) -0.30 [-0.55, -0.04] (0.02) -0.03 [-0.35, 0.29] (0.87) 
H/H 327 165 162  R/R vs H/H -0.15 [-0.64, 0.33] (0.54) 0.01 [-0.58, 0.60] (0.97) -0.37 [-1.14, 0.39] (0.34) 
R/H+H/H 2876 1393 1483  R/R vs H-carrier1 -0.13 [-0.3, 0.04] (0.13) -0.17 [-0.38, 0.03] (0.10) -0.09 [-0.35, 0.17] (0.50) 
Haplotypes % % %      
I,  1222 63.1 63.6 62.6      
II, 1212 19.7 19.3 20.2  I vs II -0.19 [-0.37, -0.01] (0.04) -0.23 [-0.45, -0.02] (0.04) -0.13 [-0.41, 0.14] (0.34) 
III, 2121 10.6 10.3 11.0  I vs III -0.09 [-0.31, 0.14] (0.46) -0.18 [-0.46, 0.10] (0.20) 0.06 [-0.30, 0.41] (0.75) 
IV, 2222 3.5 3.5 3.5  I vs IV 0.01 [-0.37, 0.40] (0.95) -0.14 [-0.61, 0.34] (0.57) 0.09 [-0.52, 0.69] (0.78) 
 
Results are the beta estimate (linear regression) with 95 % confidence interval and p values adjusted for age. 1 additive model. Haplotype designation: the allele 
with the higher prevalence is denoted with 1, the minor allele with 2. The order of polymorphisms corresponds to their position in the 5´ to 3´ direction of the 
gene: rs884115, rs13283456 (R298H), rs10987883, rs4837240. The main results are in bold. 
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